Carcinoma, Midline
Conditions
Keywords
BRD3, GSK525762, NUT Midline Carcinoma, MYCN-amplified Solid Tumor, BRD4, BET inhibitor, bromodomains, NMC, Colorectal C ancer, Small Cell Lung Cancer, Multiple Myeloma, Neuroblastoma, Oncology
Brief summary
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration of GSK525762 in the following subjects: NMC, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), neuroblastoma (NB), castration resistant prostate cancer (CRPC), triple negative breast cancer (TNBC), estrogen receptor positive (ER positive) breast cancer, and MYCN driven solid tumor subjects. Part 2 of the study will explore the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of the recommended dose from Part 1 in cohorts comprised of NMC, small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), triple negative breast cancer (TNBC), and estrogen receptor positive (ER positive) breast cancer subjects. Approximately 60 subjects will be enrolled in the Part 1 and approximately 150 subjects will be enrolled in Part 2. A sub-study will be opened in Part 1 to approximately 10-12 subjects in the United States to investigate the relative bioavailability of the besylate tablet compared to the amorphous free-base tablet at the maximum tolerated dose (MTD) or recommended phase 2 dosing (RP2D), the effect of high-fat high-calorie meal on the bioavailability of the besylate tablet at the MTD or RP2D and the dose proportionality of 2 doses of GSK525762 administered as besylate tablet.
Interventions
DRUGGSK525762
Begin at Dose Level 1 and increase up to 2 fold
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female 16 years or older, at the time of signing the informed consent. * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. If the subject is less than 18 years old, an Assent form and parental/guardian Consent form (replacing you will with your child will will be required). * Diagnosis of one of the following: Part 1 Only: NUT Midline Carcinoma based on ectopic expression of NUT protein as determined by IHC and/or detection of NUT gene translocation as determined by FISH. Subjects may be treatment naïve or have had prior therapy; SCLC, CRC, NB, TNBC, ER positive BC, CRPC, NSCLC and any other solid tumor which has been confirmed by clinical testing to be MYCN amplified (defined as a MYCN gene copy number gain of \>=5). Subjects should have tumor progression after receiving at least one prior standard/approved chemotherapy, or where there is no approved therapy, or where standard therapy is refused. Part 2 only: NUT Midline Carcinoma as diagnosed by the Central Laboratory. Subjects may be treatment naïve or have had prior therapy. SCLC, CRPC, TNBC and ER+BC . * Subjects with solid tumors, with the exception of CRPC, must demonstrate measurable disease, per RECIST v1.1. NOTE: Subjects with NMC that do not meet the RECIST v1.1 criteria for measurable disease, but have evaluable disease may be considered for enrollment after discussion with the GSK medical monitor.. * All prior treatment- related toxicities must be CTCAE (Version 4.0) \<=Grade 1 (except alopecia and peripheral neuropathy) at the time of treatment allocation \[NCI-CTCAE, 2009\]. * ECOG Performance Status score of 0 or 2 for subjects with NMC; 0-1 for subjects with other tumor types. * Adequate organ function as follows: Hematologic system: Absolute neutrophil count (ANC), Lab values - \>=1.5 X 10\^9/L; Hematologic system: Hemoglobin, Lab values - \>=9.5 grams/deciliter (g/dL) (subjects that required transfusion or growth factor need to demonstrate stable haemoglobin for 7 days of 9.5 g/ g/dL); Hematologic system: Platelets, Lab values - \>=100 X 10\^9/Liter \[L\] ); Hematologic system: Prothrombin time /International normalized ratio and partial thromboplastin time, Lab values - \<=1.5 X upper limit of normal (ULN). Renal system: Creatinine, lab values - \<=1.5 X ULN; or Renal system: Calculated creatinine clearance \[calculated by Cockcroft Gault formula\], lab values - \>=50 milliliter (mL)/minute (min); or Renal system: 24-hour urine creatinine clearance\>=50 mL/min; Hepatic system: total Bilirubin \<=1.5 X ULN (isolated bilirubin \>1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35% or subject has a diagnosis of Gilbert's syndrome), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \>=2.5 x ULN. Cardiac system: Ejection fraction, lab values - \>=lower limit of normal (LLN) by Echocardiogram (ECHO) (minimum of 50%); Cardiac system: Troponin ( T), lab values - \<=ULN; Cardiac system: Potassium, lab values - \>=LLN and \<=ULN; Cardiac system: Magnesium, lab values - \>=LLN. Thyroid system: thyroid stimulating hormone, lab values \>=LLN and \<=to ULN. Reproductive /endocrine system: testosterone \<50 nanogram (ng)/dL (only for subject with CRPC) * Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. * A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 milli international unit/mL and estradiol less than 40 pg/mL (less than 140 pmol/L) is confirmatory\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential and agrees to use one of the contraception methods (described in the protocol) for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 7 months after the last dose of study medication; Negative serum pregnancy test \<=7 days prior to first study drug dose; Female subjects who are lactating must discontinue nursing prior to the first dose of study treatment and must refrain from nursing throughout the treatment period and for 5 half-lives of GSK525762 or at least 28 days (whichever is longer) following the last dose of study treatment. * Male subjects must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until least 16 weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant while on study medication must continue to use condoms for 7 days after stopping study medications. * Specific eligibility criteria for Part 2 CRPC expansion cohort: Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuously medically castrated (for \>=8 weeks prior to pre-screening). * Specific eligibility criteria for Part 2 CRPC expansion cohort: Persistent disease with evidence of disease progression following standard therapy(ies) including prior treatment with androgen/androgen receptor directed therapy, including enzalutamide and/or abiraterone * Specific eligibility criteria for Part 2 CRPC expansion cohort: Ongoing androgen deprivation therapy with a serum testosterone level \<1.7 nanomoles/L or \<50 ng/dL. * Specific eligibility criteria for Part 2 CRPC expansion cohort: Prostate-Specific Antigen (PSA) levels \>=2.0 ng/mL. Note: If PSA level has been obtained within 14 days of Screening, this test does not need to be repeated and the result previously obtained may be used for the Screening value.
Exclusion criteria
* Primary malignancy of the central nervous system or malignancies related to human immunodeficiency virus or solid organ transplant. History of known HIV. History of known Hepatitis B surface antigen or positive Hepatitis C antibody (confirmed by RIBA). * Prior treatments usage as defined: A) Use of an investigational anti-cancer drug within 14 days or 5 half-lives, whichever is longer, prior to the first dose of the investigational products:; B) A minimum of 14 days between termination of the investigational drug and administration of GSK525762; C) Any therapy related toxicities must also have resolved to Grade 1 or less. Note that an investigational drug is defined as a drug without an approved oncologic indication; D) Chemotherapy, radiotherapy, anti-neoplastic antibody or targeted therapy or immunotherapy within 14 days, major surgery within 28 days (or 42 days for prior nitrosoureas or mitomycin C) prior to the first dose of the investigational product. Anti-androgen (e.g., bicalutamide) therapies for prostate cancer must be stopped 4 weeks prior to enrollment. Second line hormone therapies such as enzalutamide, abiraterone, or orteronel should be stopped 2 weeks prior to enrollment. Subjects with prostate cancer should remain on luteinizing hormone releasing hormone (LHRH) agonists or antagonists. Subjects with prostate cancer may also remain on low-dose prednisone or prednisolone (up to 10 mg/day) and still be eligible for this study. * Current use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days prior to the first dose of GSK525762. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with local institutional practices. * Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs (details will be available in the protocol). This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who may require a QT prolonging medication while on trial should not be enrolled. * Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes). Any serious and/or unstable pre-existing medical (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator. * Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. NOTE: Subjects previously treated for these conditions that have had stable central nervous system disease (verified with consecutive imaging studies) for \>1 month, are asymptomatic and off corticosteroids, or are on stable dose of corticosteroids for at least 1 month prior to study Day 1 are permitted. Stability of brain metastases must be confirmed with imaging. Subject treated with gamma knife the can be enrolled 2 weeks post-procedure as long as there are no post-procedure complications/stable. In addition, subjects treated or currently taking enzyme-inducing anticonvulsant are allowed on study. * Cardiac abnormalities as evidenced by any of the following: History or current untreated clinically significant uncontrolled arrhythmias; Clinically significant conduction abnormalities or arrhythmias, subjects with Bundle Branch Block; Presence of cardiac pacemaker; History or evidence of current \>=Class II congestive heart failure as defined by New York Heart Association (NYHA); History of acute coronary syndromes (including unstable angina and myocardial infarction ), coronary angioplasty, or stenting within the past 3 months. * Any of the following ECG findings: Baseline QTcF interval \>=450 millisecond (msec); Any clinically significant ECG assessments should be reviewed by the site cardiologist prior to study entry. * GSK525762 is a benzodiazepine class molecule. Any serious known immediate or delayed hypersensitivity reaction(s) to GSK525762 or idiosyncrasy to drugs chemically related to the investigational drug. * Hemoptysis \>1 teaspoon in 24 hours within the last 28 days. * History of major gastrointestinal bleeding within the last 6 months. Any evidence of active gastrointestinal bleeding excludes the subject. * Besylate Sub-Study only: unable or unwilling to eat the FDA recommended high-fat high-calorie breakfast (two eggs fried in butter, two strips of bacon, 4 ounce \[oz\]) of hash brown potatoes and 8 oz of whole milk) within the recommended 30 minutes.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study | Median of 1.87 months of drug exposure | An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment |
| Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure | Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure | Blood samples were collected for the analysis of hematology parameters: activated partial thromboplastin time (aPTT), platelet count, red blood cell count (RBC), white blood cell count (WBC), prothrombin international normalized ratio (INR), prothrombin time (PT), fibrinogen (Fib), hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure | Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog) | Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. |
| Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Baseline (pre-dose Week1 Day1) and Weeks 5,9,17 and discharge/progression | Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. |
| Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression | Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. |
| Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Baseline (pre-dose Week1 Day1), Weeks 5,9,17,25 and disc/prog | Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. |
| Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure | Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is \<60 beats per minute and \>100 beats per minute. Participants were counted twice if the participant Decreased to \<60 and Increased to \>100 post-baseline. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented |
| Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is \<60 beats per minute and \>100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Participants were counted twice if the participant Decreased to \<60 and Increased to \>100 post-baseline. |
| Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study | Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure | Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is \<60 beats per minute and \>100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure | Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented |
| Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented |
| Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure | SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure | Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Changes in Temperature From Baseline-Part 2 | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study | Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure | Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. |
| Overall Response Rate-Part 1 QD | Median of 1.38 months of drug exposure | Overall response rate is defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST version (v) 1.1). CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. |
| Overall Response Rate-Part 1 BID | Median of 1.41 months of drug exposure | Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. |
| Overall Response Rate-Part 2 | Median of 1.41 months of drug exposure | Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. |
| Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | Median of 1.38 months of drug exposure | PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals. |
| Number of Participants With PSA50 Response Rate-Part 1 BID | Median of 1.41 months of drug exposure | PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals. |
| Number of Participants With PSA50 Response-Part 2 | Median of 1.41 months of drug exposure | PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals. |
| Number of Participants With PSA50 Response-Besylate Sub-study | Median of 1.87 months of drug exposure | PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals. |
| Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose) | Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Besylate sub-study pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Parameter Population who participated in the besylate substudy. |
| Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study | Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose) | Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. |
| Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study | Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose) | Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. |
| Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study | Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose) | Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Median of 1.38 months of drug exposure | An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. All Treated Population comprised of all participants who received at least one dose of study treatment. |
| Overall Response Rate-Besylate Sub-study | Median of 1.87 months of drug exposure | Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. |
| Number of Participants With AEs and SAEs-Part 1 BID | Median of 1.41 months of drug exposure | An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment |
| Number of Participants With AEs and SAEs-Part 2 | Median of 1.41 months of drug exposure | An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. |
| Number of Participants With Dose Reductions or Delays-Part 1 QD | Median of 1.38 months of drug exposure | The number of participants who had any dose reductions or delays is presented. |
| Number of Participants With Dose Reductions or Delays-Part 1 BID | Median of 1.41 months of drug exposure | The number of participants who had any dose reductions or delays is presented. |
| Number of Participants With Dose Reductions or Delays-Part 2 | Median of 1.41 months of drug exposure | The number of participants who had any dose reductions or delays is presented. |
| Number of Participants With Dose Reductions or Delays-Besylate Sub-study | Median of 1.87 months of drug exposure | The number of participants who had any dose reductions or delays is presented. |
| Number of Participants Withdrawn Due to Toxicities-Part 1 QD | Median of 1.38 months of drug exposure | Number of participants withdrawn due to toxicities is presented. |
| Number of Participants Withdrawn Due to Toxicities-Part 1 BID | Median of 1.41 months of drug exposure | Number of participants withdrawn due to toxicities is presented. |
| Number of Participants Withdrawn Due to Toxicities-Part 2 | Median of 1.41 months of drug exposure | Number of participants withdrawn due to toxicities is presented. |
| Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study | Median of 1.87 months of drug exposure | Number of participants withdrawn due to toxicities is presented. |
| Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure | Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented. |
| Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. |
| Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure | Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides (triglyc), troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Increase in QTcF-Part 1 BID | Median of 1.41 months of drug exposure | ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. |
| Number of Participants With Increase in QTcF-Part 2 | Median of 1.41 months of drug exposure | ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. |
| Number of Participants With Increase in QTcF-Besylate Sub-study | Median of 1.87 months of drug exposure | ECG measurements were done using 12-lead ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QTcF intervals. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. |
| Progression Free Survival-Part 1 QD | Median of 1.38 months of drug exposure | Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Progression Free Survival-Part 1 BID | Median of 1.41 months of drug exposure | Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Progression Free Survival-Part 2 | Median of 1.41 months of drug exposure | Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Progression Free Survival-Besylate Sub-study | Median of 1.87 months of drug exposure | Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Time to Response-Part 1 QD | Median of 1.38 months of drug exposure | Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Time to Response-Part 1 BID | Median of 1.41 months of drug exposure | Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Time to Response-Part 2 | Median of 1.41 months of drug exposure | Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Time to Response-Besylate Sub-study | Median of 1.87 months of drug exposure | Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Duration of Response-Part 1 QD | Median of 1.38 months of drug exposure | Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Duration of Response-Part 1 BID | Median of 1.41 months of drug exposure | Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Duration of Response-Part 2 | Median of 1.41 months of drug exposure | Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Duration of Response-Besylate Sub-study | Median of 1.87 months of drug exposure | Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Overall Survival-Part 1 QD | Median of 1.38 months of drug exposure | Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Overall Survival-Part 1 BID | Median of 1.41 months of drug exposure | Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Overall Survival-Part 2 | Median of 1.41 months of drug exposure | Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. |
| Overall Survival-Besylate Sub-study | Median of 1.87 months of drug exposure | Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. |
| AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4 | Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. PK parameter population comprised of all participants in the PK Concentration Population (all participants in the All Treated Population for whom a blood sample for pharmacokinetics is obtained and analyzed) for whom a PK parameter has been obtained. |
| Maximum Observed Concentration for GSK525762-Part 1 QD | pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4 | Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. |
| Lambda z for GSK525762-Part 1 QD | pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4 | Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. |
| Tmax for GSK525762-Part 1 QD | pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4 | Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. |
| Apparent Clearance of GSK525762-Part 1 QD | pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4 | Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. |
| Volume of Distribution of GSK525762-Part 1 QD | pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4 | Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. |
| AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4 | Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. |
| Maximum Observed Concentration of GSK525762-Part 1 BID | pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4 | Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. |
| Lambda z for GSK525762-Part 1 BID | pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4 | Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. |
| Tmax for GSK525762-Part 1 BID | pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4 | Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. |
| Apparent Clearance of GSK525762-Part 1 BID | pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4 | Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. |
| Volume of Distribution of GSK525762-Part 1 BID | pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4 | Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. |
| Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Median of 1.38 months of drug exposure | Electrocardiogram (ECG) measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. |
Countries
Australia, France, Netherlands, South Korea, Spain, United Kingdom, United States
Participant flow
Recruitment details
A total 196 participants were enrolled and randomized in the Part 1 QD (65 participants), Part 1 BID (19 participants), Besylate Substudy (10 participants), and Part 2 (102 participants) groups.
Pre-assignment details
This was a 2-Part study conducted in 8 countries-Part 1 (dose-escalation) and Part 2 (dose expansion). A besylate sub-study (four period, crossover) was conducted in 10 participants in the United States.
Participants by arm
| Arm | Count |
|---|---|
| Part 1: GSK525762 4 mg QD Participants were administered once daily oral dose of 4 mg GSK525762 | 4 |
| Part 1: GSK525762 8 mg QD Participants were administered once daily oral dose of 8 mg GSK525762. | 1 |
| Part 1: GSK525762 16 mg QD Participants were administered once daily oral dose of 16 mg GSK525762. | 3 |
| Part 1: GSK525762 30 mg QD Participants were administered once daily oral dose of 30 mg GSK525762. | 4 |
| Part 1: GSK525762 60 mg QD Participants were administered once daily oral dose of 60 mg GSK525762. | 9 |
| Part 1: GSK525762 80 mg QD Participants were administered once daily oral dose of 80 mg GSK525762. | 32 |
| Part 1: GSK525762 100 mg QD Participants were administered once daily oral dose of 100 mg GSK525762. | 9 |
| Part 1: GSK525762 20 mg BID Participants were administered twice daily (BID) oral dose of 20 mg GSK525762. | 4 |
| Part 1: GSK525762 30 mg BID Participants were administered twice daily oral dose of 30 mg GSK525762. | 10 |
| Part 1: GSK525762 40 mg BID Participants were administered twice daily oral dose of 40 mg GSK525762. | 5 |
| All Participants in Besylate Substudy All participants who entered besylate sub-study and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included. | 10 |
| Part 2: Participants With NMC Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762. | 12 |
| Part 2: Participants With SCLC Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762 | 14 |
| Part 2: Participants With CRPC Participants with Castrate-Resistant Prostate Cancer (CRPR) were administered continuous once daily oral dose of 75 mg GSK525762 | 23 |
| Part 1: GSK525762 2 mg QD Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762. | 3 |
| Part 2: Participants With TNBC Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762. | 19 |
| Part 2: Participants With ER+BC Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762 | 21 |
| Part 2: Participants With GIST Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762. | 13 |
| Total | 196 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 | FG015 | FG016 | FG017 | FG018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part1 BID(Median Exposure of 1.41months) | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 9 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part1 BID(Median Exposure of 1.41months) | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part1 BID(Median Exposure of 1.41months) | Site closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part1 BID(Median Exposure of 1.41months) | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part1 QD(Median Exposure of 1.38months) | Death | 2 | 4 | 1 | 3 | 4 | 7 | 30 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part1 QD(Median Exposure of 1.38months) | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part1 QD(Median Exposure of 1.38months) | Physician Decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part1 QD(Median Exposure of 1.38months) | Site closed | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part2(Median Exposure of 1.41 Months) | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 12 | 21 | 16 | 17 | 5 | 0 | 0 |
| Part2(Median Exposure of 1.41 Months) | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Part2(Median Exposure of 1.41 Months) | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part2(Median Exposure of 1.41 Months) | Site closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 3 | 8 | 0 | 0 |
| Part2(Median Exposure of 1.41 Months) | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Substudy-P4,Maximum Exposure of 5.5month | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 4 |
| Substudy-P4,Maximum Exposure of 5.5month | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Part 2: Participants With GIST | Part 1: GSK525762 4 mg QD | Part 1: GSK525762 8 mg QD | Part 1: GSK525762 16 mg QD | Part 1: GSK525762 30 mg QD | Part 1: GSK525762 60 mg QD | Part 1: GSK525762 80 mg QD | Part 1: GSK525762 100 mg QD | Part 1: GSK525762 20 mg BID | Part 1: GSK525762 30 mg BID | Part 1: GSK525762 40 mg BID | All Participants in Besylate Substudy | Part 2: Participants With NMC | Part 2: Participants With SCLC | Part 2: Participants With CRPC | Part 1: GSK525762 2 mg QD | Part 2: Participants With TNBC | Part 2: Participants With ER+BC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 61.0 Years STANDARD_DEVIATION 13.23 | 47.0 Years STANDARD_DEVIATION 19.44 | 39.0 Years | 53.7 Years STANDARD_DEVIATION 4.19 | 49.3 Years STANDARD_DEVIATION 23.27 | 46.7 Years STANDARD_DEVIATION 17.06 | 51.5 Years STANDARD_DEVIATION 16.82 | 58.3 Years STANDARD_DEVIATION 19.92 | 66.5 Years STANDARD_DEVIATION 6.45 | 63.5 Years STANDARD_DEVIATION 8.42 | 60.4 Years STANDARD_DEVIATION 4.83 | 55.2 Years STANDARD_DEVIATION 9.96 | 42.9 Years STANDARD_DEVIATION 18.05 | 58.3 Years STANDARD_DEVIATION 11.04 | 63.8 Years STANDARD_DEVIATION 6.11 | 40.0 Years STANDARD_DEVIATION 15.77 | 50.8 Years STANDARD_DEVIATION 8.66 | 59.7 Years STANDARD_DEVIATION 10.34 | 55.4 Years STANDARD_DEVIATION 14.37 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 12 Participants |
| Race/Ethnicity, Customized Central/South Asian Heritage (Her) | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Japanese Her/East Asian Her/South East Asian Her | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 9 Participants |
| Race/Ethnicity, Customized Missing | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 8 Participants |
| Race/Ethnicity, Customized White | 10 Participants | 3 Participants | 0 Participants | 2 Participants | 4 Participants | 7 Participants | 30 Participants | 8 Participants | 3 Participants | 10 Participants | 5 Participants | 9 Participants | 6 Participants | 8 Participants | 23 Participants | 2 Participants | 15 Participants | 18 Participants | 163 Participants |
| Sex: Female, Male Female | 6 Participants | 3 Participants | 1 Participants | 3 Participants | 1 Participants | 6 Participants | 14 Participants | 2 Participants | 2 Participants | 4 Participants | 1 Participants | 5 Participants | 7 Participants | 9 Participants | 0 Participants | 1 Participants | 19 Participants | 21 Participants | 105 Participants |
| Sex: Female, Male Male | 7 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants | 3 Participants | 18 Participants | 7 Participants | 2 Participants | 6 Participants | 4 Participants | 5 Participants | 5 Participants | 5 Participants | 23 Participants | 2 Participants | 0 Participants | 0 Participants | 91 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk | EG016 affected / at risk | EG017 affected / at risk | EG018 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 4 | 1 / 1 | 3 / 3 | 4 / 4 | 7 / 9 | 30 / 32 | 7 / 9 | 1 / 4 | 9 / 10 | 3 / 5 | 8 / 12 | 12 / 14 | 21 / 23 | 2 / 3 | 16 / 19 | 17 / 21 | 5 / 13 | 1 / 5 | 0 / 5 |
| other Total, other adverse events | 4 / 4 | 1 / 1 | 3 / 3 | 3 / 4 | 9 / 9 | 31 / 32 | 9 / 9 | 4 / 4 | 10 / 10 | 5 / 5 | 11 / 12 | 14 / 14 | 23 / 23 | 3 / 3 | 19 / 19 | 21 / 21 | 12 / 13 | 5 / 5 | 5 / 5 |
| serious Total, serious adverse events | 2 / 4 | 0 / 1 | 0 / 3 | 1 / 4 | 2 / 9 | 21 / 32 | 3 / 9 | 0 / 4 | 4 / 10 | 2 / 5 | 6 / 12 | 9 / 14 | 16 / 23 | 0 / 3 | 11 / 19 | 15 / 21 | 8 / 13 | 3 / 5 | 3 / 5 |
Outcome results
Primary
Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study
Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points.
Time frame: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)
Population: Besylate Sub-Study PK Parameter Population. Only those participants with data available at the specified time points were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study | 5.628 Per hour | Geometric Coefficient of Variation 25.9 |
| Part 1: GSK525762 4 mg QD | Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study | 5.176 Per hour | Geometric Coefficient of Variation 20.6 |
| Part 1: GSK525762 8 mg QD | Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study | 5.088 Per hour | Geometric Coefficient of Variation 23.8 |
| Part 1: GSK525762 16 mg QD | Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study | 5.954 Per hour | Geometric Coefficient of Variation 20.2 |
Primary
Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study
Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Besylate sub-study pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Parameter Population who participated in the besylate substudy.
Time frame: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)
Population: Besylate Sub-Study PK Parameter Population. Only those participants with data available at the specified time points were analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to inf) | 7292.0 Hours*nanograms per milliliter | Geometric Coefficient of Variation 62.1 |
| Part 1: GSK525762 2 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to 24) | 6954.3 Hours*nanograms per milliliter | Geometric Coefficient of Variation 59.1 |
| Part 1: GSK525762 2 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to t) | 7227.1 Hours*nanograms per milliliter | Geometric Coefficient of Variation 61.6 |
| Part 1: GSK525762 4 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to t) | 7657.6 Hours*nanograms per milliliter | Geometric Coefficient of Variation 49.9 |
| Part 1: GSK525762 4 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to inf) | 7703.4 Hours*nanograms per milliliter | Geometric Coefficient of Variation 49.9 |
| Part 1: GSK525762 4 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to 24) | 7377.9 Hours*nanograms per milliliter | Geometric Coefficient of Variation 44.7 |
| Part 1: GSK525762 8 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to t) | 3053.9 Hours*nanograms per milliliter | Geometric Coefficient of Variation 44.4 |
| Part 1: GSK525762 8 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to 24) | 2977.3 Hours*nanograms per milliliter | Geometric Coefficient of Variation 42.8 |
| Part 1: GSK525762 8 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to inf) | 3096.9 Hours*nanograms per milliliter | Geometric Coefficient of Variation 45 |
| Part 1: GSK525762 16 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to inf) | 9727.7 Hours*nanograms per milliliter | Geometric Coefficient of Variation 48.5 |
| Part 1: GSK525762 16 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to 24) | 9123.8 Hours*nanograms per milliliter | Geometric Coefficient of Variation 45.2 |
| Part 1: GSK525762 16 mg QD | Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study | AUC(0 to t) | 9597.1 Hours*nanograms per milliliter | Geometric Coefficient of Variation 48.9 |
Primary
Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study
Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points.
Time frame: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)
Population: Besylate Sub-Study PK Parameter Population. Only those participants with data available at the specified time points were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study | 1431.41 Nanograms per milliliter | Geometric Coefficient of Variation 51.3 |
| Part 1: GSK525762 4 mg QD | Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study | 1483.21 Nanograms per milliliter | Geometric Coefficient of Variation 49.8 |
| Part 1: GSK525762 8 mg QD | Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study | 655.33 Nanograms per milliliter | Geometric Coefficient of Variation 21.1 |
| Part 1: GSK525762 16 mg QD | Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study | 1305.59 Nanograms per milliliter | Geometric Coefficient of Variation 46.6 |
Primary
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. All Treated Population comprised of all participants who received at least one dose of study treatment.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 9 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 21 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 31 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any AE | 9 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD | Any SAE | 3 Participants |
Primary
Number of Participants With AEs and SAEs-Part 1 BID
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With AEs and SAEs-Part 1 BID | Any AE | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With AEs and SAEs-Part 1 BID | Any SAE | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With AEs and SAEs-Part 1 BID | Any AE | 10 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With AEs and SAEs-Part 1 BID | Any SAE | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With AEs and SAEs-Part 1 BID | Any AE | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With AEs and SAEs-Part 1 BID | Any SAE | 2 Participants |
Primary
Number of Participants With AEs and SAEs-Part 2
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any SAE | 6 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any AE | 11 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any AE | 14 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any SAE | 9 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any AE | 23 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any SAE | 16 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any SAE | 11 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any AE | 19 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any AE | 21 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any SAE | 15 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any SAE | 8 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With AEs and SAEs-Part 2 | Any AE | 13 Participants |
Primary
Number of Participants With Changes in Blood Pressure From Baseline-Part 2
SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at Baseline and the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 1;n=11,14,22,19,19,12 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 2;n=11,14,22,19,19,12 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 2;n=11,14,21,19,19,12 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 3/4;n=11,14,21,19,19,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 1;n=11,14,21,19,19,12 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 3/4;n=11,14,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 1;n=11,14,22,19,19,12 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 2;n=11,14,21,19,19,12 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 2;n=11,14,22,19,19,12 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 3/4;n=11,14,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 3/4;n=11,14,21,19,19,12 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 1;n=11,14,21,19,19,12 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 2;n=11,14,21,19,19,12 | 11 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 1;n=11,14,21,19,19,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 3/4;n=11,14,22,19,19,12 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 1;n=11,14,22,19,19,12 | 8 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 2;n=11,14,22,19,19,12 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 3/4;n=11,14,21,19,19,12 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 2;n=11,14,22,19,19,12 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 1;n=11,14,22,19,19,12 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 1;n=11,14,21,19,19,12 | 9 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 3/4;n=11,14,22,19,19,12 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 3/4;n=11,14,21,19,19,12 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 2;n=11,14,21,19,19,12 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 3/4;n=11,14,22,19,19,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 1;n=11,14,22,19,19,12 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 2;n=11,14,22,19,19,12 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 1;n=11,14,21,19,19,12 | 7 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 2;n=11,14,21,19,19,12 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 3/4;n=11,14,21,19,19,12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 1;n=11,14,21,19,19,12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 3/4;n=11,14,22,19,19,12 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 2;n=11,14,22,19,19,12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | DBP; Increase to Grade 1;n=11,14,22,19,19,12 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 3/4;n=11,14,21,19,19,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Blood Pressure From Baseline-Part 2 | SBP; Increase to Grade 2;n=11,14,21,19,19,12 | 7 Participants |
Primary
Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study
Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is \<60 beats per minute and \>100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study | Pulse rate; Change to normal/no change | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study | Pulse rate; increase to >100 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study | Pulse rate; Change to normal/no change | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study | Pulse rate; increase to >100 | 4 Participants |
Primary
Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID
Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; increase to >100 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; Change to normal/no change | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; Change to normal/no change | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; increase to >100 | 6 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; increase to >100 | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID | Pulse rate; Change to normal/no change | 2 Participants |
Primary
Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD
Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is \<60 beats per minute and \>100 beats per minute. Participants were counted twice if the participant Decreased to \<60 and Increased to \>100 post-baseline. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure
Population: All Treated Population. Only those participants with data available at Baseline and the specified time point were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 12 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 18 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; Change to normal/no change | 4 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD | Pulse rate; increase to >100 | 5 Participants |
Primary
Number of Participants With Changes in Pulse Rate From Baseline-Part 2
Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is \<60 beats per minute and \>100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Participants were counted twice if the participant Decreased to \<60 and Increased to \>100 post-baseline.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at Baseline and the specified time points were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; Change to normal/no change | 7 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; increase to >100 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; Change to normal/no change | 10 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; increase to >100 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; Change to normal/no change | 13 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; increase to >100 | 9 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; increase to >100 | 9 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; decrease to <60 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; Change to normal/no change | 11 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; Change to normal/no change | 9 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; increase to >100 | 10 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; decrease to <60 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; Change to normal/no change | 8 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Pulse Rate From Baseline-Part 2 | Pulse rate; increase to >100 | 3 Participants |
Primary
Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study
Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study | Increase to >=38 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study | Change to normal/No change | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study | Change to normal/No change | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study | Increase to >=38 | 0 Participants |
Primary
Number of Participants With Changes in Temperature From Baseline-Part 1 BID
Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Increase to >=38 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Change to normal/No change | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Change to normal/No change | 9 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Increase to >=38 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Increase to >=38 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 BID | Change to normal/No change | 5 Participants |
Primary
Number of Participants With Changes in Temperature From Baseline-Part 1 QD
Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 9 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 27 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Decrease to <=35 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Change to normal/No change | 8 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 1 QD | Increase to >=38 | 0 Participants |
Primary
Number of Participants With Changes in Temperature From Baseline-Part 2
Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is \<=35 degree Celsius and \>=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at Baseline and the specified time points were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Change to normal/No change | 10 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Increase to >=38 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Decrease to <=35 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Change to normal/No change | 11 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Increase to >=38 | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Change to normal/No change | 20 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Increase to >=38 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Increase to >=38 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Change to normal/No change | 18 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Change to normal/No change | 18 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Decrease to <=35 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Increase to >=38 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Change to normal/No change | 12 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Decrease to <=35 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Changes in Temperature From Baseline-Part 2 | Increase to >=38 | 0 Participants |
Primary
Number of Participants With Dose Reductions or Delays-Besylate Sub-study
The number of participants who had any dose reductions or delays is presented.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Dose Reductions or Delays-Besylate Sub-study | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Dose Reductions or Delays-Besylate Sub-study | 1 Participants |
Primary
Number of Participants With Dose Reductions or Delays-Part 1 BID
The number of participants who had any dose reductions or delays is presented.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 BID | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 BID | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 BID | 1 Participants |
Primary
Number of Participants With Dose Reductions or Delays-Part 1 QD
The number of participants who had any dose reductions or delays is presented.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 8 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Dose Reductions or Delays-Part 1 QD | 7 Participants |
Primary
Number of Participants With Dose Reductions or Delays-Part 2
The number of participants who had any dose reductions or delays is presented.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Dose Reductions or Delays-Part 2 | 7 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Dose Reductions or Delays-Part 2 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Dose Reductions or Delays-Part 2 | 11 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Dose Reductions or Delays-Part 2 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Dose Reductions or Delays-Part 2 | 6 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Dose Reductions or Delays-Part 2 | 4 Participants |
Primary
Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study
Number of participants withdrawn due to toxicities is presented.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study | 0 Participants |
Primary
Number of Participants Withdrawn Due to Toxicities-Part 1 BID
Number of participants withdrawn due to toxicities is presented.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 BID | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 BID | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 BID | 2 Participants |
Primary
Number of Participants Withdrawn Due to Toxicities-Part 1 QD
Number of participants withdrawn due to toxicities is presented.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 7 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 1 QD | 2 Participants |
Primary
Number of Participants Withdrawn Due to Toxicities-Part 2
Number of participants withdrawn due to toxicities is presented.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 2 | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 2 | 6 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 2 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 2 | 6 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants Withdrawn Due to Toxicities-Part 2 | 2 Participants |
Primary
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study
Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Bilirubin; Any grade increase; n=5,5 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | GGT; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | HDL; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | GGT; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Bilirubin; Increase to Grade 3; n=5,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | HDL; Any grade increase; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALT; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Bilirubin; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | HDL; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Albumin; Increase to Grade 3; n=5,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Insulin; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | NT-BNP; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Insulin; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALT; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Insulin; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Potassium; Any grade increase; n=5,5 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | NT-BNP; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Potassium; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Glucose; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Potassium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CO2; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | LDL; Any grade increase; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | NT-BNP; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | LDL; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Amylase; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | LDL; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Calcium; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Lipase; Any grade increase; n=5,4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Albumin; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Lipase; Increase to Grade 3; n=5,4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Calcium; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Lipase; Increase to Grade 4;n=5,4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Amylase; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Magnesium; Any grade increase; n=5,5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Calcium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Magnesium; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CO2; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Magnesium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Cholesterol; Any grade increase; n=5,3 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Protein; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Amylase; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Protein; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Cholesterol; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Protein; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALP; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Sodium; Any grade increase; n=5,5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Cholesterol; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Sodium; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | AST; Any grade increase; n=5,5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Sodium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CK; Any grade increase; n=5,5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Thyroxine; Any grade increase; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Glucose; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Thyroxine; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CK; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Thyroxine; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | AST; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Testosterone; Any grade increase; n=2,1 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CK; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Testosterone; Increase to Grade 3; n=2,1 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALP; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Testosterone; Increase to Grade 4; n=2,1 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Chloride; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Triglycerides; Any grade increase; n=5,3 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | AST; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Triglycerides; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Chloride; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Triglycerides; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Glucose; Any grade increase; n=5,5 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin I; Any grade increase; n=1,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin I; Increase to Grade 3; n=1,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin I; Increase to Grade 4; n=1,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin T; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Chloride; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin T; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Dir bil; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin T; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALP; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urate; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Dir bil; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urate; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CO2; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urate; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Creatinine; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urea; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Albumin; Any grade increase; n=5,5 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urea; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Creatinine; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urea; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Dir bil; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Creatinine; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALT; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | GGT; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Potassium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CO2; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Insulin; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Glucose; Any grade increase; n=5,5 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Glucose; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Glucose; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Albumin; Any grade increase; n=5,5 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Albumin; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Albumin; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALP; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALP; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALP; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALT; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALT; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | ALT; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Amylase; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Amylase; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Amylase; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | AST; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | AST; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | AST; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Dir bil; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Dir bil; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Dir bil; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Bilirubin; Any grade increase; n=5,5 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Bilirubin; Increase to Grade 3; n=5,5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Bilirubin; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | NT-BNP; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | NT-BNP; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | NT-BNP; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Calcium; Any grade increase; n=5,5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Calcium; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Calcium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Cholesterol; Any grade increase; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Cholesterol; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Cholesterol; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CK; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CK; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CK; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Chloride; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Chloride; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Chloride; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CO2; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | CO2; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Creatinine; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Creatinine; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Creatinine; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | GGT; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | GGT; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | GGT; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | HDL; Any grade increase; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | HDL; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | HDL; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Insulin; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Insulin; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Potassium; Any grade increase; n=5,5 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Potassium; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | LDL; Any grade increase; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | LDL; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | LDL; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Lipase; Any grade increase; n=5,4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Lipase; Increase to Grade 3; n=5,4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Lipase; Increase to Grade 4;n=5,4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Magnesium; Any grade increase; n=5,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Magnesium; Increase to Grade 3; n=5,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Magnesium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Protein; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Protein; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Protein; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Sodium; Any grade increase; n=5,5 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Sodium; Increase to Grade 3; n=5,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Sodium; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Thyroxine; Any grade increase; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Thyroxine; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Thyroxine; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Testosterone; Any grade increase; n=2,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Testosterone; Increase to Grade 3; n=2,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Testosterone; Increase to Grade 4; n=2,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Triglycerides; Any grade increase; n=5,3 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Triglycerides; Increase to Grade 3; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Triglycerides; Increase to Grade 4; n=5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin T; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin T; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Troponin T; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urate; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urate; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urate; Increase to Grade 4; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urea; Any grade increase; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urea; Increase to Grade 3; n=5,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study | Urea; Increase to Grade 4; n=5,5 | 0 Participants |
Primary
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID
Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Increase to Grade 3; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Increase to Grade 3; n=n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Any grade increase; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Any grade increase; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Increase to Grade 3; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Increase to Grade 4; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Increase to Grade 4; n=n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Increase to Grade 3; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Increase to Grade 4; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Any grade increase; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Increase to Grade 3; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Increase to Grade 4; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Increase to Grade 4; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Any grade increase; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Any grade increase; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Increase to Grade 3; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Any grade increase; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Increase to Grade 4; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Any grade increase; n=4, 10, 5 | 7 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Increase to Grade 4; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Any grade increase; n=2, 9, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Any grade increase; n=4, 10, 5 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Any grade increase; n=4, 10, 5 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Increase to Grade 4; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Any grade increase; n=4, 10, 5 | 7 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Increase to Grade 3; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Increase to Grade 4; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Any grade increase; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Increase to Grade 3; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Increase to Grade 4; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Any grade increase; n=2, 9, 5 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Any grade increase; n=4, 10, 5 | 9 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Increase to Grade 3; n=4, 10, 5 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Any grade increase; n=4, 10, 5 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Any grade increase; n=4, 10, 5 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Increase to Grade 3; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Any grade increase; n=4, 10, 5 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Any grade increase; n=4, 10, 5 | 6 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Increase to Grade 3; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Increase to Grade 3; n=n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Increase to Grade 4; n=n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Increase to Grade 4; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Any grade increase; n=4, 10, 5 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Increase to Grade 3; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Any grade increase; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Increase to Grade 3; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Increase to Grade 4; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Creatinine; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Glucose; Any grade increase; n=4, 10, 5 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Increase to Grade 4; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | GGT; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Any grade increase; n=2, 9, 5 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Increase to Grade 4; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Increase to Grade 3; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | HDL; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Testosterone; Any grade increase; n=1, 4, 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Increase to Grade 4; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Increase to Grade 3; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Any grade increase; n=4, 10, 5 | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Thyroxine; Any grade increase; n=3, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin T; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Magnesium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Lipase; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Protein; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | LDL; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Increase to Grade 3; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Bilirubin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Increase to Grade 3; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Any grade increase; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | NT-BNP; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | AST; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Sodium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urate; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Potassium; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Calcium; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Amylase; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Any grade increase; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Dir bil; Increase to Grade 4; n=4, 9, 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Increase to Grade 3; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Cholesterol; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALT; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Triglycerides; Increase to Grade 4; n=2, 9, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Increase to Grade 3; n=n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CK; Increase to Grade 4; n=n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Any grade increase; n=3, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Insulin; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Chloride; Increase to Grade 4; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | ALP; Any grade increase; n=4, 10, 5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Urea; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Any grade increase; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | CO2; Increase to Grade 3; n=4, 10, 5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Albumin; Any grade increase; n=4, 10, 5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID | Troponin I; Increase to Grade 3; n=3, 10, 5 | 0 Participants |
Primary
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD
Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDH; Increase to Grade 4; n=0, 0, 0, 0, 0, 1, 0, 0 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDH; Any grade increase; n=0, 0, 0, 0, 0, 1, 0, 0 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDH; Increase to Grade 3; n=0, 0, 0, 0, 0, 1, 0, 0 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 7 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 12 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 11 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 14 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 4 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 9 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 11 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 17 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 17 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 5 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 15 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 10 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 16 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 3 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 24 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 7 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 7 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 8 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 13 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 11 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 9 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Any grade increase; n=2,4,1,3,4,9,31,9 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Any grade increase; n=2,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Any grade increase; n=2,4,1,3,4,9,32,9 | 8 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Chloride; Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Any grade increase; n=2,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | CK;Any grade increase;n=3,4,1,3,4,9,31,9 | 5 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Calcium; Any grade increase; n=2,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Potassium;Any grade increase;n=3,4,1,3,4,9,32,9 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Sodium;Any grade increase; n=3,4,1,3,4,9,32,9 | 4 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9 | 6 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Protein;Any grade increase; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9 | 8 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Insulin; Any grade increase; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Amylase; Any grade increase; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD | ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
Primary
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2
Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides (triglyc), troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Any grade increase;n=11,14,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 3; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 4; n=11, 14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 3; n=11,12,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Any grade increase; n=11,12,22,19,20,12 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 3; n=11, 14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Any grade increase; n=11,13,23,19,21,12 | 10 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Any grade increase; n=11, 14,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Any grade increase; n=9,9,21,17,18,11 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Any grade increase; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 4;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 3; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 3; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 3;n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 4; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 3;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Any grade increase; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Any grade increase; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Any grade increase; n=11,14,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 3; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Any grade increase; n=11,12,22,19,21,12 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade4;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade 3;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 4; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Any grade increase;n=11,14,23,19,21,12 | 8 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 3; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade3;n=10,12,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Any grade increase; n=11,13,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Any grade increase;n=10,12,22,19,20,12 | 7 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Any grade increase; n=11,13,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Any grade increase; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Any grade increase; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Any grade increase;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade4; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade3; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Any grade increase; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Any grade increase; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 3; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 3; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Any grade increase; n=11,13,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 4; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium; Any grade increase; n=11,14,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade4;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 3; n=11,13,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Any grade increase; n=11,13,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade3;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 4; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Any grade increase; n=11,12,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 4;n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 4; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Any grade increase;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Any grade increase;n=10,12,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Any grade increase; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Any grade increase; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Any grade increase; n=11,13,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 3; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 4;n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Any grade increase; n=11,13,23,19,21,12 | 10 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Any grade increase; n=11,13,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Any grade increase; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium; Any grade increase; n=11,14,23,19,21,12 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Any grade increase; n=11,13,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Any grade increase;n=10,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Any grade increase; n=9,9,21,17,18,11 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 3;n=11,12,22,19,20,12 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 3; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 4; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Any grade increase; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Any grade increase; n=11,12,22,19,21,12 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 4; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade 3;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 3; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade4;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Any grade increase; n=11,12,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Any grade increase; n=11,13,22,19,20,12 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 3;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 4;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 3; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Any grade increase; n=11, 14,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 3; n=11, 14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Any grade increase;n=11,14,23,19,21,12 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 4; n=11, 14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Any grade increase;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 4; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade3;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 4; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 3; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade4;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Any grade increase; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade3; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade4; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Any grade increase;n=10,12,22,19,20,12 | 7 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Any grade increase; n=11,13,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Any grade increase;n=11,14,23,19,21,12 | 10 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 3; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Any grade increase; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 3; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Any grade increase; n=11,12,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 4; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Any grade increase;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 3; n=11,14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Any grade increase; n=11,14,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Any grade increase;n=10,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 4; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 3; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Any grade increase;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 4;n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 3; n=11,13,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade3;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 3; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 3; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade4;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Any grade increase; n=11,13,23,19,21,12 | 8 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium; Any grade increase; n=11,14,23,19,21,12 | 10 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Any grade increase; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 4; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Any grade increase; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 4; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Any grade increase; n=11,13,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 3; n=11,13,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade3; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Any grade increase; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade3;n=11,14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Any grade increase; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade4; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Any grade increase; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Any grade increase; n=11,13,23,19,21,12 | 10 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Any grade increase; n=11,13,23,19,21,12 | 9 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Any grade increase;n=10,12,22,19,20,12 | 15 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Any grade increase;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 4; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade3;n=10,12,22,19,20,12 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Any grade increase; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade 3;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 3; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 3; n=11,13,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Any grade increase; n=11,12,22,19,21,12 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 3; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade4;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Any grade increase; n=11,12,22,19,20,12 | 7 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 4; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Any grade increase; n=11,13,22,19,20,12 | 7 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 3; n=11,13,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 4; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 3;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 3; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade4;n=11,14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 3; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 4;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Any grade increase; n=11,13,23,19,21,12 | 20 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Any grade increase; n=9,9,21,17,18,11 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade3;n=11,14,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Any grade increase; n=11, 14,23,19,21,12 | 8 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Any grade increase; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Any grade increase;n=11,14,23,19,21,12 | 13 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 3; n=11, 14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Any grade increase;n=11,14,23,19,21,12 | 9 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Any grade increase; n=11,12,22,19,20,12 | 9 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 4; n=11, 14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Any grade increase; n=11,14,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 3; n=11,13,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Any grade increase; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 3; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 4; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Any grade increase;n=11,14,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Any grade increase; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Any grade increase; n=11,13,23,19,21,12 | 4 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Any grade increase;n=10,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Any grade increase; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 3; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 4; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Any grade increase; n=11,12,22,19,21,12 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade 3;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade4;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 3;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 4;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Any grade increase; n=11, 14,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 3; n=11, 14,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 4; n=11, 14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Any grade increase;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade3;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade4;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Any grade increase; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade3; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade4; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Any grade increase;n=10,12,22,19,20,12 | 10 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Any grade increase; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 3; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 4; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Any grade increase;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Any grade increase; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 3; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 4;n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Any grade increase; n=11,13,23,19,21,12 | 16 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Any grade increase; n=11,13,23,19,21,12 | 8 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Any grade increase; n=11,13,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Any grade increase; n=11,14,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 3; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Any grade increase; n=11,12,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 3; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Any grade increase; n=11,13,23,19,21,12 | 8 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Any grade increase; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 3; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 4; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Any grade increase;n=11,14,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Any grade increase; n=11,13,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 3; n=11,13,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 4; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium; Any grade increase; n=11,14,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Any grade increase; n=11,12,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 3;n=11,12,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 4;n=11,12,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Any grade increase; n=11,12,22,19,21,12 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 3; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 3; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 4; n=11,13,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Any grade increase; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 4; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade4;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade3;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 3; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Any grade increase; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 3; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Any grade increase; n=9,9,21,17,18,11 | 7 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade3;n=10,12,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Any grade increase;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Any grade increase;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 3; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Any grade increase; n=11,12,22,19,20,12 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 4; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Any grade increase;n=10,12,22,19,20,12 | 9 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 4; n=11, 14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Any grade increase;n=10,12,22,19,20,12 | 11 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 3; n=11, 14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 3; n=11,13,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Any grade increase;n=11,14,23,19,21,12 | 13 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Any grade increase;n=11,14,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Any grade increase; n=11,13,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Any grade increase; n=11,13,23,19,21,12 | 14 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium; Any grade increase; n=11,14,23,19,21,12 | 7 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Any grade increase; n=11, 14,23,19,21,12 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Any grade increase; n=11,12,22,19,20,12 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 4; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Any grade increase; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 4;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade4; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Any grade increase; n=11,13,23,19,21,12 | 7 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 3;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 3; n=11,13,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 3; n=11,13,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 3; n=11,13,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Any grade increase; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Any grade increase; n=11,13,23,19,21,12 | 18 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade3; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 4;n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 4; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 3; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Any grade increase; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 4;n=11,12,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Any grade increase; n=11,13,23,19,21,12 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Any grade increase; n=11,13,22,19,20,12 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade4;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 3; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade 3;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 3; n=11,13,22,19,20,12 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Any grade increase; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Any grade increase; n=11,14,23,19,21,12 | 12 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Any grade increase; n=11,14,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Any grade increase;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 3; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 4; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Any grade increase;n=11,14,23,19,21,12 | 4 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALT; Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Increase to Grade 3; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin I; Any grade increase; n=7,6,15,15,14,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Any grade increase; n=11,12,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Amylase; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Triglyc;Any grade increase;n=10,12,22,19,20,12 | 8 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade4; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 4; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Increase to Grade3; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Testosterone; Any grade increase; n=4,3,18,0,1,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade4;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 3;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Any grade increase; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Increase to Grade3;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 3; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Thyroxine; Any grade increase;n=7,7,20,15,18,8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 4; n=11, 14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CO2; Increase to Grade 4; n=11,12,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Increase to Grade 3; n=11, 14,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Increase to Grade 4;n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Any grade increase;n=11,14,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Sodium; Any grade increase; n=11, 14,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 4;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Increase to Grade 3; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade3;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Increase to Grade 3;n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Creatinine;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Protein; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade4;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Any grade increase; n=11,13,22,19,20,12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Increase to Grade 3;n=11,12,22,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | LDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 3; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Magnesium; Any grade increase; n=11,12,22,19,21,12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Chloride; Any grade increase; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | GGT; Increase to Grade 4; n=11,13,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 4; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Dir bil; Any grade increase; n=11,13,23,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Any grade increase; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Increase to Grade 3; n=9,9,21,17,18,11 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | CK; Any grade increase; n=9,9,21,17,18,11 | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 3; n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade4;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Any grade increase; n=11,13,23,19,21,12 | 6 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | HDL; Increase to Grade 4;n=10,10,22,19,19,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Increase to Grade3;n=10,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Cholesterol;Any grade increase;n=10,12,22,19,20,12 | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Any grade increase; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Lipase; Any grade increase; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Calcium; Any grade increase; n=11,13,23,19,21,12 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Insulin; Increase to Grade 4; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium; Any grade increase; n=11,14,23,19,21,12 | 7 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | NT-BNP; Any grade increase; n=11,12,22,17,15,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | AST; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade3;n=11,14,23,19,21,12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Any grade increase; n=11,13,23,19,21,12 | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Increase to Grade 3; n=11,13,23,19,21,12 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Glucose; Any grade increase; n=11,13,23,19,21,12 | 9 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 4;n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Increase to Grade 3; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Albumin; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urea; Any grade increase; n=11,14,23,17,17,11 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Any grade increase; n=11,13,23,19,21,12 | 4 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 4; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Increase to Grade 3; n=11,12,22,19,20,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 3; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Urate; Any grade increase; n=11,12,22,19,20,12 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Potassium;Increase to Grade4;n=11,14,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | ALP; Increase to Grade 4; n=11,13,23,19,21,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 | Troponin T;Increase to Grade4;n=11,12,22,19,20,12 | 0 Participants |
Primary
Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study
Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Basophils; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Basophils; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Basophils; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Eosinophils; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Eosinophils; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Eosinophils; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Hemoglobin; Any grade increase | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Hemoglobin; Increase to Grade 3 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Hemoglobin; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | INR; Any grade increase | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | INR; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Lymphocytes; Any grade increase | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Lymphocytes; Increase to Grade 3 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Lymphocytes; Increase to Grade 4 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Monocytes; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Monocytes; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Monocytes; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Neutrophils; Any grade increase | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Neutrophils; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Neutrophils; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Platelets; Any grade increase | 5 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Platelets; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Platelets; Increase to Grade 4 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | RBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | RBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | WBC; Any grade increase | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Fib; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Fib; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | aPTT; Any grade increase | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Neutrophils; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | RBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Basophils; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Neutrophils; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Basophils; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Basophils; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Fib; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Eosinophils; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Platelets; Any grade increase | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Eosinophils; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | WBC; Any grade increase | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Eosinophils; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Platelets; Increase to Grade 3 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Hemoglobin; Any grade increase | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Hemoglobin; Increase to Grade 3 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Platelets; Increase to Grade 4 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Hemoglobin; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | INR; Any grade increase | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | INR; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Fib; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Lymphocytes; Any grade increase | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Lymphocytes; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Lymphocytes; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Monocytes; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Monocytes; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Monocytes; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | RBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | Neutrophils; Any grade increase | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study | aPTT; Any grade increase | 2 Participants |
Primary
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID
Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Increase to Grade4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Increase to Grade4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Any grade increase;n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes;Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Any grade increase; n=4,10,5 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Any grade increase; n=4,10,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Any grade increase; n=4,10,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Any grade increase; n=4,10,5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Increase to Grade4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Any grade increase; n=4,10,5 | 8 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Increase to Grade 3; n=4,10,5 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Any grade increase; n=4,10,5 | 6 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Any grade increase; n=4,10,5 | 8 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Increase to Grade3; n=4,10,5 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Increase to Grade4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes;Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Any grade increase; n=4,10,5 | 10 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Increase to Grade 3; n=4,10,5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Any grade increase;n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Any grade increase; n=4,10,5 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Any grade increase; n=4,10,5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | INR; Any grade increase; n=4,10,5 | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | RBC; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Any grade increase; n=4,10,5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Increase to Grade 3; n=4,10,5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Hemoglobin; Any grade increase; n=4,10,5 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Any grade increase; n=4,10,5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | WBC; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Increase to Grade4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Neutrophils; Any grade increase; n=4,10,5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Basophils; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Any grade increase; n=4,10,5 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Increase to Grade 3; n=4,10,5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes;Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Eosinophils; Increase to Grade3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Platelets; Increase to Grade 4; n=4,10,5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Monocytes; Any grade increase; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | aPTT; Increase to Grade 4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Any grade increase;n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Lymphocytes; Increase to Grade4; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | Fib; Increase to Grade 3; n=4,10,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID | PT; Increase to Grade 3; n=4,10,5 | 0 Participants |
Primary
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD
Blood samples were collected for the analysis of hematology parameters: activated partial thromboplastin time (aPTT), platelet count, red blood cell count (RBC), white blood cell count (WBC), prothrombin international normalized ratio (INR), prothrombin time (PT), fibrinogen (Fib), hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 00 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 8 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 21 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 9 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 21 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 7 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 4 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 19 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 14 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 5 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 11 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 26 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 11 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 3 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Any grade increase | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC; Any grade increase | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Monocytes;Any grade increase | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade4 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Increase to Grade3 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Lymphocytes;Any grade increase | 4 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | RBC;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | aPTT; Any grade increase | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Any grade increase | 5 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | INR; Any grade increase | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 3 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Basophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | WBC; Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Hemoglobin;Any grade increase | 7 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade 4 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Increase to Grade3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Fib; Any grade increase | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 4 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Eosinophils;Any grade increase | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | PT; Any grade increase | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Increase to Grade 3 | 5 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Platelets;Any grade increase | 8 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD | Neutrophils;Increase to Grade 4 | 0 Participants |
Primary
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2
Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Any grade increase;n=11,14,23,19,21,13 | 6 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Any grade increase;n=11,13,23,19,21,13 | 8 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade3; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Any grade increase; n=11,12,21,17,18,12 | 8 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Any grade increase; n=11, 11, 21, 17, 18, 12 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Any grade increase; n=11, 14, 23, 19, 21, 13 | 7 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Any grade increase; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Any grade increase;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Any grade increase;n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade4; n=11,14,23,19,21,13 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade3; n=11,14,23,19,21,13 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade3;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Any grade increase; n=11,12,21,17,18,12 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Any grade increase; n=11,14,23,19,21,13 | 7 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade4;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade3;n=11,14,23,19,21,13 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Any grade increase;n=11,14,23,19,21,13 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes;Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Any grade increase; n=11,12,21,17,18,12 | 6 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Any grade increase;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade3;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Any grade increase;n=11,14,23,19,21,13 | 10 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade3; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Any grade increase;n=11,13,23,19,21,13 | 7 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes;Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Any grade increase;n=11,14,23,19,21,13 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade3;n=11,14,23,19,21,13 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade4;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Any grade increase; n=11,14,23,19,21,13 | 12 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade3; n=11,14,23,19,21,13 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade4; n=11,14,23,19,21,13 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Any grade increase;n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Any grade increase; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Any grade increase; n=11, 14, 23, 19, 21, 13 | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Any grade increase; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Any grade increase; n=11,12,21,17,18,12 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade3;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13 | 9 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Any grade increase;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Any grade increase;n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade4; n=11,14,23,19,21,13 | 8 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade4;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Any grade increase;n=11,14,23,19,21,13 | 18 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Any grade increase; n=11,12,21,17,18,12 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade3; n=11,14,23,19,21,13 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade3;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Any grade increase; n=11,14,23,19,21,13 | 20 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Any grade increase; n=11, 11, 21, 17, 18, 12 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13 | 6 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes;Increase to Grade3; n=11,13,23,19,21,13 | 00 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Any grade increase;n=11,13,23,19,21,13 | 14 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Any grade increase; n=11, 14, 23, 19, 21, 13 | 9 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade3; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Any grade increase;n=11,14,23,19,21,13 | 8 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Any grade increase; n=11,12,21,17,18,12 | 13 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Any grade increase; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Any grade increase;n=11,13,23,19,21,13 | 9 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes;Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Any grade increase;n=11,14,23,19,21,13 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade3;n=11,14,23,19,21,13 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade3;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade4;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Any grade increase; n=11,14,23,19,21,13 | 17 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade3; n=11,14,23,19,21,13 | 6 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Any grade increase;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Any grade increase; n=11,12,21,17,18,12 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Any grade increase;n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Any grade increase; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Any grade increase; n=11, 14, 23, 19, 21, 13 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade4; n=11,14,23,19,21,13 | 4 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Any grade increase; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13 | 4 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Any grade increase; n=11,12,21,17,18,12 | 8 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade3; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Any grade increase;n=11,14,23,19,21,13 | 10 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Any grade increase; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Any grade increase; n=11, 14, 23, 19, 21, 13 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Any grade increase;n=11,14,23,19,21,13 | 18 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Any grade increase; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade3;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13 | 5 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Any grade increase; n=11,12,21,17,18,12 | 11 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes;Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Any grade increase; n=11,14,23,19,21,13 | 18 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Any grade increase;n=11,13,23,19,21,13 | 13 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade3; n=11,14,23,19,21,13 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Any grade increase;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade4;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade4; n=11,14,23,19,21,13 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Any grade increase;n=11,14,23,19,21,13 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Any grade increase;n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade3; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade3;n=11,14,23,19,21,13 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Any grade increase; n=11,12,21,17,18,12 | 5 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Any grade increase; n=11,12,21,17,18,12 | 4 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Any grade increase;n=11,14,23,19,21,13 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Any grade increase; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Increase to Grade3;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Any grade increase; n=11,12,21,17,18,12 | 7 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes;Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade3; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Any grade increase; n=11, 14, 23, 19, 21, 13 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Monocytes; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | INR; Increase to Grade3; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Any grade increase;n=11,13,23,19,21,13 | 6 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Any grade increase; n=11, 11, 21, 17, 18, 12 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Any grade increase; n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | aPTT; Increase to Grade4; n=11,12,21,17,18,12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Any grade increase; n=11,14,23,19,21,13 | 7 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Eosinophils;Any grade increase;n=11,13,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade4;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade3; n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Platelets; Increase to Grade4; n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Neutrophils;Increase to Grade3;n=11,14,23,19,21,13 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | PT; Any grade increase;n=10,10, 18, 17, 18, 12 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Hemoglobin;Any grade increase;n=11,14,23,19,21,13 | 6 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 | Basophils; Increase to Grade4; n=11,13,23,19,21,13 | 0 Participants |
Primary
Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study
SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | DBP; Increase to Grade 2 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | SBP; Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | DBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | SBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | DBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | SBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | DBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | DBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | SBP; Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study | DBP; Increase to Grade 2 | 1 Participants |
Primary
Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID
SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at Baseline and the specified time point were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 1;n=4,10,4 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 2;n=4,10,4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 3/4;n=4,10,4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 1;n=4,9,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 2;n=4,9,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 3/4;n=4,9,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 3/4;n=4,9,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 1;n=4,10,4 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 1;n=4,9,5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 2;n=4,9,5 | 6 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 2;n=4,10,4 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 3/4;n=4,10,4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 2;n=4,10,4 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 3/4;n=4,10,4 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 3/4;n=4,9,5 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 1;n=4,9,5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | DBP; Increase to Grade 1;n=4,10,4 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID | SBP; Increase to Grade 2;n=4,9,5 | 1 Participants |
Primary
Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (\<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (\>=160) and DBP: Grade 0 (\<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (\>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented
Time frame: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 3 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 11 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 10 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 9 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 9 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 5 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 3/4 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 1 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 1 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 2 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | SBP; Increase to Grade 3/4 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD | DBP; Increase to Grade 2 | 1 Participants |
Primary
Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study
Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
Time frame: Baseline (pre-dose Week1 Day1), Weeks 5,9,17,25 and disc/prog
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; Week9; n=4,1 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Leukocytes; disc/prog; n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Hyaline casts; Week5;n=1,1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Protein; Week5; n=3,2 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Protein; Week9; n=4,1 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Protein; Week17; n=2,0 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Protein; Week25; n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Erythrocytes; Week9; n=4,1 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Erythrocytes; Week17; n=2,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Erythrocytes; Week25; n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Erythrocytes; disc/prog; n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; Week5; n=3,2 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Leukocytes; Week25; n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; Week17; n=2,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; Week25; n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; disc/prog; n=2,2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Leukocytes; Week5; n=3,1 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Leukocytes; Week9; n=4,1 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Leukocytes; Week17; n=2,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Hyaline casts; Week9;n=2,1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Hyaline casts; Week17;n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Hyaline casts; Week25;n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Glucose; Week5;n=3,2 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Glucose; Week9;n=4,1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Glucose; Week17;n=2,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Ketones; Week9;n=4,1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;Week5;n=3,2 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;Week9;n=4,1 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;Week17;n=2,0 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;Week25;n=1,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;disc/prog;n=2,2 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Hyaline casts; Week5;n=1,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Leukocytes; Week9; n=4,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Hyaline casts; Week9;n=2,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; Week5; n=3,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Erythrocytes; Week9; n=4,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;disc/prog;n=2,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Glucose; Week5;n=3,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Leukocytes; Week5; n=3,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Glucose; Week9;n=4,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Protein; Week5; n=3,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; Week9; n=4,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Ketones; Week9;n=4,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Protein; Week9; n=4,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;Week5;n=3,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | Specific gravity; disc/prog; n=2,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study | pH;Week9;n=4,1 | 0 Participants |
Primary
Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID
Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
Time frame: Baseline (pre-dose Week1 Day1) and Weeks 5,9,17 and discharge/progression
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Erythrocytes; Week 5;n=1,5,1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; Week 5;n=2,7,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Occult blood; Week 5;n=2,7,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; Week 5;n=2,7,3 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; Week 5;n=2,7,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Ketones; Week 5;n=2,7,3 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; Week 5;n=2,7,3 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Leukocytes; Week 5;n=1,5,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Occult blood; Week 9;n=0,4,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Occult blood; disc/prog;n=0,6,1 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; Week 5;n=2,7,3 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; Week 5;n=2,7,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; Week 9;n=0,4,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; Week 17;n=0,2,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; disc/prog;n=0,6,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Ketones; Week 5;n=2,7,3 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Ketones; Week 17;n=0,2,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Occult blood; Week 5;n=2,7,3 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; Week 5;n=2,7,3 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; Week 9;n=0,4,2 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; Week 17;n=0,2,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; disc/prog;n=0,7,1 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; Week 5;n=2,7,3 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; Week 9;n=0,4,2 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; Week 17;n=0,2,0 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; disc/prog;n=0,7,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Erythrocytes; Week 5;n=1,5,1 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Erythrocytes; Week 9;n=0,1,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Erythrocytes; Week 17;n=0,1,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; Week 9;n=0,4,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; Week 17;n=0,2,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; disc/prog;n=0,7,1 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Leukocytes; Week 5;n=1,5,1 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Leukocytes; Week 9;n=0,1,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Leukocytes; Week 17;n=0,1,0 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Ketones; Week 5;n=2,7,3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Leukocytes; Week 9;n=0,1,1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Erythrocytes; Week 5;n=1,5,1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Occult blood; disc/prog;n=0,6,1 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Occult blood; Week 9;n=0,4,2 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Leukocytes; Week 5;n=1,5,1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; Week 5;n=2,7,3 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Erythrocytes; Week 9;n=0,1,1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; Week 9;n=0,4,2 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; disc/prog;n=0,7,1 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; disc/prog;n=0,6,1 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | pH; disc/prog;n=0,7,1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Occult blood; Week 5;n=2,7,3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; Week 9;n=0,4,2 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; Week 5;n=2,7,3 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; Week 5;n=2,7,3 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; Week 9;n=0,4,2 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Glucose; Week 5;n=2,7,3 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Specific gravity; Week 9;n=0,4,2 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID | Protein; disc/prog;n=0,7,1 | 1 Participants |
Primary
Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD
Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
Time frame: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 9; n=1,1,0,1,1,3,12,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 9; n=1,1,0,1,1,3,11,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 9; n=1,1,0,1,1,1,6,4 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 9; n=1,1,0,1,1,1,6,4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Disc/Prog; n=0,1,0,1,0,3,17,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 33; n=0,1,0,0,0,0,2,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 9; n=1,1,0,1,1,3,11,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 17; n=0,1,0,0,0,0,1,2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 17; n=0, 1,0,0,0,0,5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 33; n=0,1,0,0,0,0,2,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 9; n=1,1,0,1,1,3,12,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 17; n=0,1,0,0,0,0,5,3 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 17; n=0,1,0,0,0,0,5,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 33; n=0,1,0,0,0,0,2,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 9; n=1,1,0,1,1,1,6,4 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 9; n=1,1,0,1,1,3,11,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 9; n=1,1,0,1,1,1,6,4 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 9; n=1,1,0,1,1,3,11,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 9; n=1,1,0,1,1,3,12,5 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Disc/Prog; n=0,1,0,1,0,3,17,2 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 9; n=1,1,0,1,1,3,11,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 9; n=1,1,0,1,1,1,6,4 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 9; n=1,1,0,1,1,3,12,5 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 41; n=0,0,0,0,0,0,1,0 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Cellular casts; Week 17; n=0,0, 0, 0, 0,0,1,0 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 4 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 9; n=1,1,0,1,1,3,12,5 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 9; n=1,1,0,1,1,3,11,5 | 3 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 17; n=0, 1,0,0,0,0,5,3 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 33; n=0,1,0,0,0,0,2,0 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2 | 2 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 6 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 8 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 33; n=0,1,0,0,0,0,2,0 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Disc/Prog; n=0,1,0,1,0,3,17,2 | 9 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 9 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 9; n=1,1,0,1,1,3,12,5 | 7 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 17; n=0,1,0,0,0,0,5,3 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Disc/Prog; n=0,1,0,1,0,3,17,2 | 5 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 7 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 9; n=1,1,0,1,1,3,12,5 | 6 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 17; n=0,1,0,0,0,0,5,3 | 4 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 33; n=0,1,0,0,0,0,2,0 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2 | 6 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 49; n=0,0,0,0,0,0,1,0 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 4 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 9; n=1,1,0,1,1,1,6,4 | 3 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 17; n=0,1,0,0,0,0,1,2 | 1 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1 | 4 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 9; n=1,1,0,1,1,3,12,5 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Week 5; n=1, 2, 1, 3,2,7,20,7 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 17; n=0,1,0,0,0,0,1,2 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 5; n=1, 2,1,3,2,7,20,7 | 4 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 17; n=0, 1,0,0,0,0,5,3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 9; n=1,1,0,1,1,3,11,5 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Occult blood;Week 5; n=1,2,1,3,2,7,17,7 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 9; n=1,1,0,1,1,3,12,5 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Ketones;Week 5; n=1,2,1,3,2,7,20,7 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 5; n=1,2,1,2,2,6,11,6 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 25; n=0,1,0,0,0,0,3,1 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Glucose;Week 5; n=1,2,1,3,2,7,20,7 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 5; n=1,2,1,3,2,7,20,7 | 5 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Disc/Prog; n=0,1,0,1,0,3,17,2 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 25; n=0,1,0,0,0,0,3,1 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 17; n=0,1,0,0,0,0,5,3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 17; n=0,1,0,0,0,0,5,3 | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Specific gravity;Week 9; n=1,1,0,1,1,3,12,5 | 4 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Protein;Week 9; n=1,1,0,1,1,3,12,5 | 3 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Leukocytes;Week 9; n=1,1,0,1,1,1,6,4 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | pH;Disc/Prog; n=0,1,0,1,0,3,17,2 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD | Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3 | 1 Participants |
Primary
Number of Participants With Maximum Urinalysis Change From Baseline-Part 2
Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
Time frame: Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression
Population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week73;n=1,0,0,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;disc/prog;n=3,6,16,12,12,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week5;n=3,3,8,4,4,4 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week13;n=7,2,6,1,2,2 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week25;n=2,0,3,0,0,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week85;n=1,0,0,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week37;n=3,0,1,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week13;n=7,2,6,1,2,2 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week13;n=7,2,6,1,2,2 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week5;n=8,7,18,12,14,8 | 6 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week37;n=3,0,1,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week13;n=1,1,0,0,0,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week5;n=3,3,8,4,4,4 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week9;n=8,3,12,3,6,5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week5;n=1,2,2,2,4,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week9;n=8,3,12,3,6,5 | 5 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week49;n=1,0,1,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week5;n=8,7,18,12,14,8 | 4 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week5;n=8,7,18,12,14,8 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;disc/prog;n=1,2,6,3,4,2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week13;n=7,2,6,1,2,2 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week37;n=3,0,1,0,0,0 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week9;n=8,3,12,3,6,5 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week13;n=3,1,0,0,0,1 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week9;n=4,0,2,2,1,2 | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week25;n=2,0,3,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week 5;n=8,7,18,12,14,8 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;disc/prog;n=3,6,16,12,12,5 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week5;n=8,7,18,12,14,8 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week37;n=1,0,1,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week49;n=1,0,1,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week73;n=1,0,0,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;disc/prog;n=1,2,7,3,4,1 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week25;n=2,0,1,0,0,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week9;n=8,3,12,3,6,5 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week85;n=1,0,0,0,0,0 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week13;n=3,1,0,0,0,1 | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week9;n=4,0,2,2,1,3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week9;n=8,3,12,3,6,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week5;n=8,7,18,12,14,8 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week5;n=3,3,8,4,4,4 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;disc/prog;n=3,6,16,12,12,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week5;n=8,7,18,12,14,8 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week9;n=8,3,12,3,6,5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week13;n=1,1,0,0,0,0 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week9;n=8,3,12,3,6,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week5;n=1,2,2,2,4,0 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;disc/prog;n=3,6,16,12,12,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;disc/prog;n=3,6,16,12,12,5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;Week5;n=0,2,2,1,3,0 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;disc/prog;n=1,2,7,3,4,1 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week9;n=8,3,12,3,6,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week13;n=3,1,0,0,0,1 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week5;n=3,3,8,4,4,4 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;disc/prog;n=3,6,16,12,12,5 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week5;n=8,7,18,12,14,8 | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week9;n=8,3,12,3,6,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week5;n=8,7,18,12,14,8 | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week9;n=8,3,12,3,6,5 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week 5;n=8,7,18,12,14,8 | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;disc/prog;n=1,2,6,3,4,2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week13;n=3,1,0,0,0,1 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week37;n=3,0,1,0,0,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week49;n=1,0,1,0,0,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;disc/prog;n=3,6,16,12,12,5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week5;n=8,7,18,12,14,8 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week9;n=8,3,12,3,6,5 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week25;n=2,0,3,0,0,0 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week37;n=3,0,1,0,0,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;disc/prog;n=3,6,16,12,12,5 | 8 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week5;n=8,7,18,12,14,8 | 8 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week9;n=8,3,12,3,6,5 | 7 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week13;n=7,2,6,1,2,2 | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week25;n=2,0,3,0,0,0 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week37;n=3,0,1,0,0,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week49;n=1,0,1,0,0,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;disc/prog;n=3,6,16,12,12,5 | 6 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week5;n=8,7,18,12,14,8 | 9 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week9;n=8,3,12,3,6,5 | 4 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week13;n=7,2,6,1,2,2 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week37;n=1,0,1,0,0,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;disc/prog;n=3,6,16,12,12,5 | 6 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week5;n=3,3,8,4,4,4 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week9;n=4,0,2,2,1,2 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;disc/prog;n=1,2,6,3,4,2 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week5;n=8,7,18,12,14,8 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week9;n=8,3,12,3,6,5 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;disc/prog;n=3,6,16,12,12,5 | 3 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week5;n=3,3,8,4,4,4 | 5 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week9;n=4,0,2,2,1,3 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week25;n=2,0,1,0,0,0 | 1 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;disc/prog;n=1,2,7,3,4,1 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;Week5;n=0,2,2,1,3,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;disc/prog;n=1,2,6,3,4,0 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week5;n=1,2,2,2,4,0 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week9;n=0,0,1,2,1,1 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;disc/prog;n=1,2,6,3,4,0 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week 5;n=8,7,18,12,14,8 | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week 5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;disc/prog;n=3,6,16,12,12,5 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;disc/prog;n=1,2,6,3,4,2 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;Week5;n=0,2,2,1,3,0 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;disc/prog;n=3,6,16,12,12,5 | 6 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week5;n=3,3,8,4,4,4 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week9;n=8,3,12,3,6,5 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;disc/prog;n=1,2,7,3,4,1 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week9;n=4,0,2,2,1,3 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week5;n=8,7,18,12,14,8 | 5 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week5;n=8,7,18,12,14,8 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week9;n=0,0,1,2,1,1 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week9;n=8,3,12,3,6,5 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;disc/prog;n=3,6,16,12,12,5 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week5;n=1,2,2,2,4,0 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week5;n=8,7,18,12,14,8 | 3 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week9;n=4,0,2,2,1,2 | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week5;n=3,3,8,4,4,4 | 2 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week5;n=3,3,8,4,4,4 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week9;n=4,0,2,2,1,2 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week9;n=8,3,12,3,6,5 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;disc/prog;n=1,2,6,3,4,2 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week5;n=8,7,18,12,14,8 | 7 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week5;n=8,7,18,12,14,8 | 6 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week9;n=8,3,12,3,6,5 | 5 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;disc/prog;n=3,6,16,12,12,5 | 5 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week 5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week5;n=3,3,8,4,4,4 | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week9;n=4,0,2,2,1,3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;disc/prog;n=3,6,16,12,12,5 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;disc/prog;n=1,2,7,3,4,1 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;Week5;n=0,2,2,1,3,0 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;disc/prog;n=3,6,16,12,12,5 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week5;n=1,2,2,2,4,0 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week9;n=0,0,1,2,1,1 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week5;n=8,7,18,12,14,8 | 5 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week5;n=8,7,18,12,14,8 | 1 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;disc/prog;n=3,6,16,12,12,5 | 3 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;disc/prog;n=3,6,16,12,12,5 | 5 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week9;n=8,3,12,3,6,5 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Granular cast;disc/prog;n=1,2,6,3,4,0 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;disc/prog;n=3,6,16,12,12,5 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week9;n=8,3,12,3,6,5 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week13;n=3,1,0,0,0,1 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week13;n=7,2,6,1,2,2 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Hyaline cast;Week9;n=0,0,1,2,1,1 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;disc/prog;n=3,6,16,12,12,5 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week9;n=8,3,12,3,6,5 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week5;n=8,7,18,12,14,8 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week5;n=8,7,18,12,14,8 | 6 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | pH;Week5;n=8,7,18,12,14,8 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week13;n=3,1,0,0,0,1 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;disc/prog;n=1,2,6,3,4,2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week5;n=3,3,8,4,4,4 | 2 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week9;n=4,0,2,2,1,3 | 3 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Glucose;Week 5;n=8,7,18,12,14,8 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week9;n=8,3,12,3,6,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Protein;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;disc/prog;n=1,2,7,3,4,1 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;disc/prog;n=3,6,16,12,12,5 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Leukocytes;Week5;n=3,3,8,4,4,4 | 4 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;disc/prog;n=3,6,16,12,12,5 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Erythrocytes;Week9;n=4,0,2,2,1,2 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Ketones;Week5;n=8,7,18,12,14,8 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Occult blood;Week13;n=7,2,6,1,2,2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Maximum Urinalysis Change From Baseline-Part 2 | Specific gravity;Week13;n=7,2,6,1,2,2 | 1 Participants |
Primary
Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study | Any non-serious AE | 5 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study | Any SAE | 3 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study | Any non-serious AE | 5 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study | Any SAE | 3 Participants |
Primary
Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD
PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 2 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD | 1 Participants |
Primary
Number of Participants With PSA50 Response-Besylate Sub-study
PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With PSA50 Response-Besylate Sub-study | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With PSA50 Response-Besylate Sub-study | 0 Participants |
Primary
Number of Participants With PSA50 Response-Part 2
PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With PSA50 Response-Part 2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With PSA50 Response-Part 2 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With PSA50 Response-Part 2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With PSA50 Response-Part 2 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With PSA50 Response-Part 2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With PSA50 Response-Part 2 | 0 Participants |
Primary
Number of Participants With PSA50 Response Rate-Part 1 BID
PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline \>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \>=50% reduction is presented along with 95% confidence intervals.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With PSA50 Response Rate-Part 1 BID | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With PSA50 Response Rate-Part 1 BID | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With PSA50 Response Rate-Part 1 BID | 0 Participants |
Primary
Overall Response Rate-Besylate Sub-study
Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Response Rate-Besylate Sub-study | 0 Percentage of participants |
Primary
Overall Response Rate-Part 1 BID
Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Response Rate-Part 1 BID | 0 Percentage of participants |
| Part 1: GSK525762 4 mg QD | Overall Response Rate-Part 1 BID | 0 Percentage of participants |
| Part 1: GSK525762 8 mg QD | Overall Response Rate-Part 1 BID | 0 Percentage of participants |
Primary
Overall Response Rate-Part 1 QD
Overall response rate is defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST version (v) 1.1). CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Response Rate-Part 1 QD | 0 Percentage of participants |
| Part 1: GSK525762 4 mg QD | Overall Response Rate-Part 1 QD | 25 Percentage of participants |
| Part 1: GSK525762 8 mg QD | Overall Response Rate-Part 1 QD | 0 Percentage of participants |
| Part 1: GSK525762 16 mg QD | Overall Response Rate-Part 1 QD | 0 Percentage of participants |
| Part 1: GSK525762 30 mg QD | Overall Response Rate-Part 1 QD | 0 Percentage of participants |
| Part 1: GSK525762 60 mg QD | Overall Response Rate-Part 1 QD | 0 Percentage of participants |
| Part 1: GSK525762 80 mg QD | Overall Response Rate-Part 1 QD | 3 Percentage of participants |
| Part 1: GSK525762 100 mg QD | Overall Response Rate-Part 1 QD | 11 Percentage of participants |
Primary
Overall Response Rate-Part 2
Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Response Rate-Part 2 | 8 Percentage of participants |
| Part 1: GSK525762 4 mg QD | Overall Response Rate-Part 2 | 0 Percentage of participants |
| Part 1: GSK525762 8 mg QD | Overall Response Rate-Part 2 | 4 Percentage of participants |
| Part 1: GSK525762 16 mg QD | Overall Response Rate-Part 2 | 0 Percentage of participants |
| Part 1: GSK525762 30 mg QD | Overall Response Rate-Part 2 | 0 Percentage of participants |
| Part 1: GSK525762 60 mg QD | Overall Response Rate-Part 2 | 0 Percentage of participants |
Primary
Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study
Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points.
Time frame: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)
Population: Besylate Sub-Study PK Parameter Population. Only those participants with data available at the specified time points were analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study | 0.5833 Hours |
| Part 1: GSK525762 4 mg QD | Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study | 0.8083 Hours |
| Part 1: GSK525762 8 mg QD | Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study | 0.8333 Hours |
| Part 1: GSK525762 16 mg QD | Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study | 2.0000 Hours |
Secondary
Apparent Clearance of GSK525762-Part 1 BID
Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 23.246 Liter per hour | Geometric Coefficient of Variation 124.4 |
| Part 1: GSK525762 2 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week1 PM dose;n=4,7,5 | 21.745 Liter per hour | Geometric Coefficient of Variation 82.7 |
| Part 1: GSK525762 2 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 16.731 Liter per hour | Geometric Coefficient of Variation 110.1 |
| Part 1: GSK525762 2 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 18.867 Liter per hour | Geometric Coefficient of Variation 96 |
| Part 1: GSK525762 4 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 20.133 Liter per hour | Geometric Coefficient of Variation 26.2 |
| Part 1: GSK525762 4 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 9.621 Liter per hour | Geometric Coefficient of Variation 45.3 |
| Part 1: GSK525762 4 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 11.949 Liter per hour | Geometric Coefficient of Variation 86.1 |
| Part 1: GSK525762 4 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week1 PM dose;n=4,7,5 | 11.057 Liter per hour | Geometric Coefficient of Variation 48.1 |
| Part 1: GSK525762 8 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 37.097 Liter per hour | Geometric Coefficient of Variation 29.4 |
| Part 1: GSK525762 8 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week1 PM dose;n=4,7,5 | 16.382 Liter per hour | Geometric Coefficient of Variation 34.6 |
| Part 1: GSK525762 8 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 34.623 Liter per hour | Geometric Coefficient of Variation 18.7 |
| Part 1: GSK525762 8 mg QD | Apparent Clearance of GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 14.155 Liter per hour | Geometric Coefficient of Variation 32.8 |
Secondary
Apparent Clearance of GSK525762-Part 1 QD
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 11.467 Liter per hour | Geometric Coefficient of Variation 44.3 |
| Part 1: GSK525762 2 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 13.082 Liter per hour | — |
| Part 1: GSK525762 4 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 11.085 Liter per hour | Geometric Coefficient of Variation 35.1 |
| Part 1: GSK525762 4 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 11.955 Liter per hour | Geometric Coefficient of Variation 60.5 |
| Part 1: GSK525762 8 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 18.470 Liter per hour | — |
| Part 1: GSK525762 8 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 24.277 Liter per hour | — |
| Part 1: GSK525762 16 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 18.036 Liter per hour | Geometric Coefficient of Variation 39.1 |
| Part 1: GSK525762 16 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 23.823 Liter per hour | Geometric Coefficient of Variation 21.4 |
| Part 1: GSK525762 30 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 6.720 Liter per hour | Geometric Coefficient of Variation 62.9 |
| Part 1: GSK525762 30 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 9.535 Liter per hour | Geometric Coefficient of Variation 54.5 |
| Part 1: GSK525762 60 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 13.769 Liter per hour | Geometric Coefficient of Variation 42.1 |
| Part 1: GSK525762 60 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 23.296 Liter per hour | Geometric Coefficient of Variation 47.3 |
| Part 1: GSK525762 80 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 27.029 Liter per hour | Geometric Coefficient of Variation 48.4 |
| Part 1: GSK525762 80 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 13.589 Liter per hour | Geometric Coefficient of Variation 62.8 |
| Part 1: GSK525762 100 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 13.707 Liter per hour | Geometric Coefficient of Variation 45.2 |
| Part 1: GSK525762 100 mg QD | Apparent Clearance of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 26.188 Liter per hour | Geometric Coefficient of Variation 35.8 |
Secondary
AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID
Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week3 AM dose;n=3,7,3 | 1279.0 Hours*nanogram per milliter | Geometric Coefficient of Variation 116.2 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week3 PM dose;n=3,6,3 | 1053.6 Hours*nanogram per milliter | Geometric Coefficient of Variation 96.6 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week3 PM dose;n=3,5,3 | 1155.8 Hours*nanogram per milliter | Geometric Coefficient of Variation 102.4 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week1 PM dose;n=4,9,5 | 927.5 Hours*nanogram per milliter | Geometric Coefficient of Variation 82.5 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week3 AM dose;n=3,7,3 | 1194.6 Hours*nanogram per milliter | Geometric Coefficient of Variation 110.1 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to inf); Week1 AM dose;n=3,10,5 | 860.4 Hours*nanogram per milliter | Geometric Coefficient of Variation 124.4 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week1 AM dose;n=3,10,5 | 856.1 Hours*nanogram per milliter | Geometric Coefficient of Variation 123.7 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week1 PM dose;n=4,7,5 | 981.4 Hours*nanogram per milliter | Geometric Coefficient of Variation 84.8 |
| Part 1: GSK525762 2 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week1 AM dose;n=4,10,5 | 932.2 Hours*nanogram per milliter | Geometric Coefficient of Variation 97.6 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week3 AM dose;n=3,7,3 | 2725.3 Hours*nanogram per milliter | Geometric Coefficient of Variation 92.4 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week1 PM dose;n=4,7,5 | 3261.1 Hours*nanogram per milliter | Geometric Coefficient of Variation 59.9 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week1 PM dose;n=4,9,5 | 2840.4 Hours*nanogram per milliter | Geometric Coefficient of Variation 43.4 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week3 AM dose;n=3,7,3 | 2472.4 Hours*nanogram per milliter | Geometric Coefficient of Variation 89.8 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week3 PM dose;n=3,6,3 | 1490.8 Hours*nanogram per milliter | Geometric Coefficient of Variation 23.3 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week1 AM dose;n=4,10,5 | 2727.2 Hours*nanogram per milliter | Geometric Coefficient of Variation 40.8 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week1 AM dose;n=3,10,5 | 3067.0 Hours*nanogram per milliter | Geometric Coefficient of Variation 43.9 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week3 PM dose;n=3,5,3 | 1662.1 Hours*nanogram per milliter | Geometric Coefficient of Variation 29.2 |
| Part 1: GSK525762 4 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to inf); Week1 AM dose;n=3,10,5 | 3118.3 Hours*nanogram per milliter | Geometric Coefficient of Variation 45.3 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week3 PM dose;n=3,6,3 | 1073.6 Hours*nanogram per milliter | Geometric Coefficient of Variation 29.2 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week1 AM dose;n=3,10,5 | 2794.4 Hours*nanogram per milliter | Geometric Coefficient of Variation 31.8 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week1 PM dose;n=4,7,5 | 2607.6 Hours*nanogram per milliter | Geometric Coefficient of Variation 36.2 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week3 AM dose;n=3,7,3 | 1184.6 Hours*nanogram per milliter | Geometric Coefficient of Variation 17.8 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to 24); Week3 PM dose;n=3,5,3 | 1131.6 Hours*nanogram per milliter | Geometric Coefficient of Variation 28.5 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to inf); Week1 AM dose;n=3,10,5 | 2825.8 Hours*nanogram per milliter | Geometric Coefficient of Variation 32.8 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week1 AM dose;n=4,10,5 | 2579.0 Hours*nanogram per milliter | Geometric Coefficient of Variation 28 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week1 PM dose;n=4,9,5 | 2446.7 Hours*nanogram per milliter | Geometric Coefficient of Variation 34.2 |
| Part 1: GSK525762 8 mg QD | AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID | AUC (0 to t); Week3 AM dose;n=3,7,3 | 1140.9 Hours*nanogram per milliter | Geometric Coefficient of Variation 16.9 |
Secondary
AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. PK parameter population comprised of all participants in the PK Concentration Population (all participants in the All Treated Population for whom a blood sample for pharmacokinetics is obtained and analyzed) for whom a PK parameter has been obtained.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
Population: PK Parameter Population. Only those participants with data available at the specified time points were available (indicated by n=X in category titles)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 169.2 Hours*nanogram per milliliter | Geometric Coefficient of Variation 39.4 |
| Part 1: GSK525762 2 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 152.8 Hours*nanogram per milliliter | — |
| Part 1: GSK525762 2 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 168.6 Hours*nanogram per milliliter | Geometric Coefficient of Variation 44.5 |
| Part 1: GSK525762 2 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 174.4 Hours*nanogram per milliliter | Geometric Coefficient of Variation 44.3 |
| Part 1: GSK525762 2 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 152.9 Hours*nanogram per milliliter | — |
| Part 1: GSK525762 4 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 334.6 Hours*nanogram per milliliter | Geometric Coefficient of Variation 60.5 |
| Part 1: GSK525762 4 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 357.5 Hours*nanogram per milliliter | Geometric Coefficient of Variation 34.8 |
| Part 1: GSK525762 4 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 334.3 Hours*nanogram per milliliter | Geometric Coefficient of Variation 60.3 |
| Part 1: GSK525762 4 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 360.8 Hours*nanogram per milliliter | Geometric Coefficient of Variation 35.1 |
| Part 1: GSK525762 4 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 354.3 Hours*nanogram per milliliter | Geometric Coefficient of Variation 33.8 |
| Part 1: GSK525762 8 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 329.5 Hours*nanogram per milliliter | — |
| Part 1: GSK525762 8 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 330.6 Hours*nanogram per milliliter | — |
| Part 1: GSK525762 8 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 431.5 Hours*nanogram per milliliter | — |
| Part 1: GSK525762 8 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 431.1 Hours*nanogram per milliliter | — |
| Part 1: GSK525762 8 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 433.1 Hours*nanogram per milliliter | — |
| Part 1: GSK525762 16 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 887.1 Hours*nanogram per milliliter | Geometric Coefficient of Variation 39.1 |
| Part 1: GSK525762 16 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 672.3 Hours*nanogram per milliliter | Geometric Coefficient of Variation 21.5 |
| Part 1: GSK525762 16 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 867.9 Hours*nanogram per milliliter | Geometric Coefficient of Variation 39.5 |
| Part 1: GSK525762 16 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 671.6 Hours*nanogram per milliliter | Geometric Coefficient of Variation 21.4 |
| Part 1: GSK525762 16 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 877.7 Hours*nanogram per milliliter | Geometric Coefficient of Variation 39.4 |
| Part 1: GSK525762 30 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 4464.5 Hours*nanogram per milliliter | Geometric Coefficient of Variation 62.9 |
| Part 1: GSK525762 30 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 3943.2 Hours*nanogram per milliliter | Geometric Coefficient of Variation 49.5 |
| Part 1: GSK525762 30 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 3146.2 Hours*nanogram per milliliter | Geometric Coefficient of Variation 54.5 |
| Part 1: GSK525762 30 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 4147.8 Hours*nanogram per milliliter | Geometric Coefficient of Variation 54.3 |
| Part 1: GSK525762 30 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 3164.3 Hours*nanogram per milliliter | Geometric Coefficient of Variation 54.7 |
| Part 1: GSK525762 60 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 4357.5 Hours*nanogram per milliliter | Geometric Coefficient of Variation 42.1 |
| Part 1: GSK525762 60 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 4304.1 Hours*nanogram per milliliter | Geometric Coefficient of Variation 40.7 |
| Part 1: GSK525762 60 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 2575.6 Hours*nanogram per milliliter | Geometric Coefficient of Variation 47.3 |
| Part 1: GSK525762 60 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 4225.0 Hours*nanogram per milliliter | Geometric Coefficient of Variation 39.2 |
| Part 1: GSK525762 60 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 2576.9 Hours*nanogram per milliliter | Geometric Coefficient of Variation 47.3 |
| Part 1: GSK525762 80 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 5887.2 Hours*nanogram per milliliter | Geometric Coefficient of Variation 62.8 |
| Part 1: GSK525762 80 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 5692.4 Hours*nanogram per milliliter | Geometric Coefficient of Variation 61.4 |
| Part 1: GSK525762 80 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 2959.8 Hours*nanogram per milliliter | Geometric Coefficient of Variation 48.4 |
| Part 1: GSK525762 80 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 2953.8 Hours*nanogram per milliliter | Geometric Coefficient of Variation 49 |
| Part 1: GSK525762 80 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 5667.3 Hours*nanogram per milliliter | Geometric Coefficient of Variation 61.5 |
| Part 1: GSK525762 100 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6 | 3819.9 Hours*nanogram per milliliter | Geometric Coefficient of Variation 35.9 |
| Part 1: GSK525762 100 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9 | 7218.4 Hours*nanogram per milliliter | Geometric Coefficient of Variation 45.1 |
| Part 1: GSK525762 100 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9 | 6958.3 Hours*nanogram per milliliter | Geometric Coefficient of Variation 43.5 |
| Part 1: GSK525762 100 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9 | 7295.6 Hours*nanogram per milliliter | Geometric Coefficient of Variation 45.2 |
| Part 1: GSK525762 100 mg QD | AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD | AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6 | 3818.5 Hours*nanogram per milliliter | Geometric Coefficient of Variation 35.8 |
Secondary
Duration of Response-Besylate Sub-study
Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Duration of Response-Part 1 BID
Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Duration of Response-Part 1 QD
Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Duration of Response-Part 2
Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a confirmed CR or PR. Duration of response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Lambda z for GSK525762-Part 1 BID
Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Lambda z for GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 0.23463 Per hour | Geometric Coefficient of Variation 19.4 |
| Part 1: GSK525762 2 mg QD | Lambda z for GSK525762-Part 1 BID | Week1 PM dose;n=3,7,3 | 0.21171 Per hour | Geometric Coefficient of Variation 23.1 |
| Part 1: GSK525762 2 mg QD | Lambda z for GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 0.23565 Per hour | Geometric Coefficient of Variation 27.2 |
| Part 1: GSK525762 2 mg QD | Lambda z for GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 0.20507 Per hour | Geometric Coefficient of Variation 21.5 |
| Part 1: GSK525762 4 mg QD | Lambda z for GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 0.19263 Per hour | Geometric Coefficient of Variation 27.7 |
| Part 1: GSK525762 4 mg QD | Lambda z for GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 0.19989 Per hour | Geometric Coefficient of Variation 29.6 |
| Part 1: GSK525762 4 mg QD | Lambda z for GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 0.21751 Per hour | Geometric Coefficient of Variation 27.7 |
| Part 1: GSK525762 4 mg QD | Lambda z for GSK525762-Part 1 BID | Week1 PM dose;n=3,7,3 | 0.14307 Per hour | Geometric Coefficient of Variation 36.6 |
| Part 1: GSK525762 8 mg QD | Lambda z for GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 0.29133 Per hour | Geometric Coefficient of Variation 15.8 |
| Part 1: GSK525762 8 mg QD | Lambda z for GSK525762-Part 1 BID | Week1 PM dose;n=3,7,3 | 0.18789 Per hour | Geometric Coefficient of Variation 25.2 |
| Part 1: GSK525762 8 mg QD | Lambda z for GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 0.30868 Per hour | Geometric Coefficient of Variation 19.6 |
| Part 1: GSK525762 8 mg QD | Lambda z for GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 0.23721 Per hour | Geometric Coefficient of Variation 39.4 |
Secondary
Lambda z for GSK525762-Part 1 QD
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.21411 Per hour | Geometric Coefficient of Variation 98.4 |
| Part 1: GSK525762 2 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.15579 Per hour | — |
| Part 1: GSK525762 4 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.13554 Per hour | Geometric Coefficient of Variation 37.4 |
| Part 1: GSK525762 4 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.15472 Per hour | Geometric Coefficient of Variation 11.2 |
| Part 1: GSK525762 8 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.23126 Per hour | — |
| Part 1: GSK525762 8 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.14087 Per hour | — |
| Part 1: GSK525762 16 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.09903 Per hour | Geometric Coefficient of Variation 43.5 |
| Part 1: GSK525762 16 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.15599 Per hour | Geometric Coefficient of Variation 21.7 |
| Part 1: GSK525762 30 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.07863 Per hour | Geometric Coefficient of Variation 53.1 |
| Part 1: GSK525762 30 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.12513 Per hour | Geometric Coefficient of Variation 12.7 |
| Part 1: GSK525762 60 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.12468 Per hour | Geometric Coefficient of Variation 28.2 |
| Part 1: GSK525762 60 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.17629 Per hour | Geometric Coefficient of Variation 26.3 |
| Part 1: GSK525762 80 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.16667 Per hour | Geometric Coefficient of Variation 30.6 |
| Part 1: GSK525762 80 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.15613 Per hour | Geometric Coefficient of Variation 34.1 |
| Part 1: GSK525762 100 mg QD | Lambda z for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.10992 Per hour | Geometric Coefficient of Variation 16 |
| Part 1: GSK525762 100 mg QD | Lambda z for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.17560 Per hour | Geometric Coefficient of Variation 21.1 |
Secondary
Maximum Observed Concentration for GSK525762-Part 1 QD
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 52.04 Nanogram per milliliter | — |
| Part 1: GSK525762 2 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 50.95 Nanogram per milliliter | Geometric Coefficient of Variation 41.5 |
| Part 1: GSK525762 4 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 70.46 Nanogram per milliliter | Geometric Coefficient of Variation 29.2 |
| Part 1: GSK525762 4 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 53.37 Nanogram per milliliter | Geometric Coefficient of Variation 16.3 |
| Part 1: GSK525762 8 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 103.18 Nanogram per milliliter | — |
| Part 1: GSK525762 8 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 120.35 Nanogram per milliliter | — |
| Part 1: GSK525762 16 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 137.57 Nanogram per milliliter | Geometric Coefficient of Variation 25.1 |
| Part 1: GSK525762 16 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 179.45 Nanogram per milliliter | Geometric Coefficient of Variation 39.9 |
| Part 1: GSK525762 30 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 602.70 Nanogram per milliliter | Geometric Coefficient of Variation 17.2 |
| Part 1: GSK525762 30 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 603.92 Nanogram per milliliter | Geometric Coefficient of Variation 30.3 |
| Part 1: GSK525762 60 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 633.71 Nanogram per milliliter | Geometric Coefficient of Variation 52.6 |
| Part 1: GSK525762 60 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 889.52 Nanogram per milliliter | Geometric Coefficient of Variation 24.5 |
| Part 1: GSK525762 80 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 1099.81 Nanogram per milliliter | Geometric Coefficient of Variation 62.7 |
| Part 1: GSK525762 80 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 815.40 Nanogram per milliliter | Geometric Coefficient of Variation 41.1 |
| Part 1: GSK525762 100 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 918.56 Nanogram per milliliter | Geometric Coefficient of Variation 41.4 |
| Part 1: GSK525762 100 mg QD | Maximum Observed Concentration for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 1080.49 Nanogram per milliliter | Geometric Coefficient of Variation 38.8 |
Secondary
Maximum Observed Concentration of GSK525762-Part 1 BID
Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week1 AM dose;n=4,10,5 | 231.68 Nanogram per milliter | Geometric Coefficient of Variation 70.6 |
| Part 1: GSK525762 2 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week1 PM dose;n=4,9,5 | 166.62 Nanogram per milliter | Geometric Coefficient of Variation 62 |
| Part 1: GSK525762 2 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 284.71 Nanogram per milliter | Geometric Coefficient of Variation 87.1 |
| Part 1: GSK525762 2 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week3 PM dose;n=3,6,3 | 256.08 Nanogram per milliter | Geometric Coefficient of Variation 94 |
| Part 1: GSK525762 4 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week3 PM dose;n=3,6,3 | 263.72 Nanogram per milliter | Geometric Coefficient of Variation 41.3 |
| Part 1: GSK525762 4 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week1 AM dose;n=4,10,5 | 628.01 Nanogram per milliter | Geometric Coefficient of Variation 40 |
| Part 1: GSK525762 4 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 604.38 Nanogram per milliter | Geometric Coefficient of Variation 66.4 |
| Part 1: GSK525762 4 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week1 PM dose;n=4,9,5 | 445.17 Nanogram per milliter | Geometric Coefficient of Variation 27.6 |
| Part 1: GSK525762 8 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week3 PM dose;n=3,6,3 | 229.91 Nanogram per milliter | Geometric Coefficient of Variation 34.8 |
| Part 1: GSK525762 8 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week1 PM dose;n=4,9,5 | 425.76 Nanogram per milliter | Geometric Coefficient of Variation 29.3 |
| Part 1: GSK525762 8 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 419.15 Nanogram per milliter | Geometric Coefficient of Variation 18.1 |
| Part 1: GSK525762 8 mg QD | Maximum Observed Concentration of GSK525762-Part 1 BID | Week1 AM dose;n=4,10,5 | 703.31 Nanogram per milliter | Geometric Coefficient of Variation 34.2 |
Secondary
Number of Participants With Increase in QTcF-Besylate Sub-study
ECG measurements were done using 12-lead ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QTcF intervals. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Besylate Sub-study | Any Grade increase | 2 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Besylate Sub-study | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Besylate Sub-study | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Besylate Sub-study | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Besylate Sub-study | Any Grade increase | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Besylate Sub-study | Increase to Grade 3 | 0 Participants |
Secondary
Number of Participants With Increase in QTcF-Part 1 BID
ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Increase to Grade 2 | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Any Grade increase | 3 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Any Grade increase | 4 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Any Grade increase | 2 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QTcF-Part 1 BID | Increase to Grade 2 | 0 Participants |
Secondary
Number of Participants With Increase in QTcF-Part 2
ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population. Only those participants with data available at the specified time point were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Part 2 | Any Grade increase | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 3 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Part 2 | Any Grade increase | 2 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QTcF-Part 2 | Any Grade increase | 6 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in QTcF-Part 2 | Any Grade increase | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in QTcF-Part 2 | Any Grade increase | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 2 | 2 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in QTcF-Part 2 | Any Grade increase | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in QTcF-Part 2 | Increase to Grade 2 | 0 Participants |
Secondary
Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD
Electrocardiogram (ECG) measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (\<450 milliseconds \[msec\]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (\>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 1 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 2 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 1 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 4 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 0 Participants |
| Part 1: GSK525762 8 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 1 Participants |
| Part 1: GSK525762 16 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 4 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 30 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 60 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 4 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 13 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 0 Participants |
| Part 1: GSK525762 80 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 0 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 2 | 1 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Any Grade increase | 4 Participants |
| Part 1: GSK525762 100 mg QD | Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD | Increase to Grade 3 | 0 Participants |
Secondary
Overall Survival-Besylate Sub-study
Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Survival-Besylate Sub-study | 6.3 Months |
Secondary
Overall Survival-Part 1 BID
Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Survival-Part 1 BID | NA Months |
| Part 1: GSK525762 4 mg QD | Overall Survival-Part 1 BID | 6.0 Months |
| Part 1: GSK525762 8 mg QD | Overall Survival-Part 1 BID | 13.3 Months |
Secondary
Overall Survival-Part 1 QD
Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Survival-Part 1 QD | 0.6 Months |
| Part 1: GSK525762 4 mg QD | Overall Survival-Part 1 QD | 4.1 Months |
| Part 1: GSK525762 8 mg QD | Overall Survival-Part 1 QD | 2.2 Months |
| Part 1: GSK525762 16 mg QD | Overall Survival-Part 1 QD | 9.1 Months |
| Part 1: GSK525762 30 mg QD | Overall Survival-Part 1 QD | 3.8 Months |
| Part 1: GSK525762 60 mg QD | Overall Survival-Part 1 QD | 8.9 Months |
| Part 1: GSK525762 80 mg QD | Overall Survival-Part 1 QD | 7.1 Months |
| Part 1: GSK525762 100 mg QD | Overall Survival-Part 1 QD | 9.8 Months |
Secondary
Overall Survival-Part 2
Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Overall Survival-Part 2 | 5.0 Months |
| Part 1: GSK525762 4 mg QD | Overall Survival-Part 2 | 2.6 Months |
| Part 1: GSK525762 8 mg QD | Overall Survival-Part 2 | 9.1 Months |
| Part 1: GSK525762 16 mg QD | Overall Survival-Part 2 | 5.0 Months |
| Part 1: GSK525762 30 mg QD | Overall Survival-Part 2 | 8.8 Months |
| Part 1: GSK525762 60 mg QD | Overall Survival-Part 2 | 7.3 Months |
Secondary
Progression Free Survival-Besylate Sub-study
Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Progression Free Survival-Besylate Sub-study | 3.5 Months |
Secondary
Progression Free Survival-Part 1 BID
Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Progression Free Survival-Part 1 BID | 7.7 Months |
| Part 1: GSK525762 4 mg QD | Progression Free Survival-Part 1 BID | 5.6 Months |
| Part 1: GSK525762 8 mg QD | Progression Free Survival-Part 1 BID | 8.0 Months |
Secondary
Progression Free Survival-Part 1 QD
Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Progression Free Survival-Part 1 QD | 0.3 Months |
| Part 1: GSK525762 4 mg QD | Progression Free Survival-Part 1 QD | 4.1 Months |
| Part 1: GSK525762 8 mg QD | Progression Free Survival-Part 1 QD | 2.2 Months |
| Part 1: GSK525762 16 mg QD | Progression Free Survival-Part 1 QD | 9.1 Months |
| Part 1: GSK525762 30 mg QD | Progression Free Survival-Part 1 QD | 3.8 Months |
| Part 1: GSK525762 60 mg QD | Progression Free Survival-Part 1 QD | 3.6 Months |
| Part 1: GSK525762 80 mg QD | Progression Free Survival-Part 1 QD | 6.5 Months |
| Part 1: GSK525762 100 mg QD | Progression Free Survival-Part 1 QD | 7.5 Months |
Secondary
Progression Free Survival-Part 2
Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1: GSK525762 2 mg QD | Progression Free Survival-Part 2 | 4.8 Months |
| Part 1: GSK525762 4 mg QD | Progression Free Survival-Part 2 | 2.2 Months |
| Part 1: GSK525762 8 mg QD | Progression Free Survival-Part 2 | 8.0 Months |
| Part 1: GSK525762 16 mg QD | Progression Free Survival-Part 2 | 2.4 Months |
| Part 1: GSK525762 30 mg QD | Progression Free Survival-Part 2 | 4.7 Months |
| Part 1: GSK525762 60 mg QD | Progression Free Survival-Part 2 | 3.4 Months |
Secondary
Time to Response-Besylate Sub-study
Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.87 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Time to Response-Part 1 BID
Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Time to Response-Part 1 QD
Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.38 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Time to Response-Part 2
Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Time to response is not derived for participants with incomplete response dates. Confidence intervals were estimated using Brookmeyer Crowley method.
Time frame: Median of 1.41 months of drug exposure
Population: All Treated Population. Participants with incomplete response dates were excluded from the analysis.
Secondary
Tmax for GSK525762-Part 1 BID
Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Tmax for GSK525762-Part 1 BID | Week1 AM dose;n=4,10,5 | 1.5500 Hour |
| Part 1: GSK525762 2 mg QD | Tmax for GSK525762-Part 1 BID | Week1 PM dose;n=4,9,5 | 1.9583 Hour |
| Part 1: GSK525762 2 mg QD | Tmax for GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 1.1833 Hour |
| Part 1: GSK525762 2 mg QD | Tmax for GSK525762-Part 1 BID | Week3 PM dose;n=3,6,3 | 1.0000 Hour |
| Part 1: GSK525762 4 mg QD | Tmax for GSK525762-Part 1 BID | Week3 PM dose;n=3,6,3 | 1.4500 Hour |
| Part 1: GSK525762 4 mg QD | Tmax for GSK525762-Part 1 BID | Week1 AM dose;n=4,10,5 | 0.9667 Hour |
| Part 1: GSK525762 4 mg QD | Tmax for GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 1.0667 Hour |
| Part 1: GSK525762 4 mg QD | Tmax for GSK525762-Part 1 BID | Week1 PM dose;n=4,9,5 | 1.9667 Hour |
| Part 1: GSK525762 8 mg QD | Tmax for GSK525762-Part 1 BID | Week3 PM dose;n=3,6,3 | 2.0667 Hour |
| Part 1: GSK525762 8 mg QD | Tmax for GSK525762-Part 1 BID | Week1 PM dose;n=4,9,5 | 1.9833 Hour |
| Part 1: GSK525762 8 mg QD | Tmax for GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 0.5833 Hour |
| Part 1: GSK525762 8 mg QD | Tmax for GSK525762-Part 1 BID | Week1 AM dose;n=4,10,5 | 0.5500 Hour |
Secondary
Tmax for GSK525762-Part 1 QD
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 0.5833 Hours |
| Part 1: GSK525762 2 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 1.0000 Hours |
| Part 1: GSK525762 4 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 1.2250 Hours |
| Part 1: GSK525762 4 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 2.5083 Hours |
| Part 1: GSK525762 8 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 1.1000 Hours |
| Part 1: GSK525762 8 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.5000 Hours |
| Part 1: GSK525762 16 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 2.0167 Hours |
| Part 1: GSK525762 16 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 1.0500 Hours |
| Part 1: GSK525762 30 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 2.0083 Hours |
| Part 1: GSK525762 30 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.9000 Hours |
| Part 1: GSK525762 60 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 1.0000 Hours |
| Part 1: GSK525762 60 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 1.0583 Hours |
| Part 1: GSK525762 80 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 0.5667 Hours |
| Part 1: GSK525762 80 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 1.0000 Hours |
| Part 1: GSK525762 100 mg QD | Tmax for GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 1.0000 Hours |
| Part 1: GSK525762 100 mg QD | Tmax for GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 1.5000 Hours |
Secondary
Volume of Distribution of GSK525762-Part 1 BID
Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 71.00 Liters | Geometric Coefficient of Variation 72.8 |
| Part 1: GSK525762 2 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week1 PM dose;n=3,7,3 | 116.52 Liters | Geometric Coefficient of Variation 66 |
| Part 1: GSK525762 2 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 99.07 Liters | Geometric Coefficient of Variation 91 |
| Part 1: GSK525762 2 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 92.00 Liters | Geometric Coefficient of Variation 65.3 |
| Part 1: GSK525762 4 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week1 PM dose;n=3,7,3 | 77.28 Liters | Geometric Coefficient of Variation 16.6 |
| Part 1: GSK525762 4 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 48.13 Liters | Geometric Coefficient of Variation 40.8 |
| Part 1: GSK525762 4 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 104.52 Liters | Geometric Coefficient of Variation 29.5 |
| Part 1: GSK525762 4 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 54.94 Liters | Geometric Coefficient of Variation 61.4 |
| Part 1: GSK525762 8 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week1 AM dose;n=3,10,5 | 59.67 Liters | Geometric Coefficient of Variation 35 |
| Part 1: GSK525762 8 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week3 PM dose;n=3,5,3 | 127.34 Liters | Geometric Coefficient of Variation 41.7 |
| Part 1: GSK525762 8 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week3 AM dose;n=3,7,3 | 112.17 Liters | Geometric Coefficient of Variation 37.6 |
| Part 1: GSK525762 8 mg QD | Volume of Distribution of GSK525762-Part 1 BID | Week1 PM dose;n=3,7,3 | 81.11 Liters | Geometric Coefficient of Variation 52.6 |
Secondary
Volume of Distribution of GSK525762-Part 1 QD
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762.
Time frame: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 53.56 Liters | Geometric Coefficient of Variation 65.9 |
| Part 1: GSK525762 2 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 83.97 Liters | — |
| Part 1: GSK525762 4 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 77.27 Liters | Geometric Coefficient of Variation 47 |
| Part 1: GSK525762 4 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 81.79 Liters | Geometric Coefficient of Variation 34.7 |
| Part 1: GSK525762 8 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 79.87 Liters | — |
| Part 1: GSK525762 8 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 172.33 Liters | — |
| Part 1: GSK525762 16 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 152.72 Liters | Geometric Coefficient of Variation 44.5 |
| Part 1: GSK525762 16 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 182.13 Liters | Geometric Coefficient of Variation 92.7 |
| Part 1: GSK525762 30 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 85.46 Liters | Geometric Coefficient of Variation 30.3 |
| Part 1: GSK525762 30 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 76.20 Liters | Geometric Coefficient of Variation 44 |
| Part 1: GSK525762 60 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 132.14 Liters | Geometric Coefficient of Variation 34.7 |
| Part 1: GSK525762 60 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 110.44 Liters | Geometric Coefficient of Variation 23.5 |
| Part 1: GSK525762 80 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 162.17 Liters | Geometric Coefficient of Variation 40.6 |
| Part 1: GSK525762 80 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 87.03 Liters | Geometric Coefficient of Variation 56.4 |
| Part 1: GSK525762 100 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week1;n=3,4,1,3,4,9,32,9 | 124.70 Liters | Geometric Coefficient of Variation 42.6 |
| Part 1: GSK525762 100 mg QD | Volume of Distribution of GSK525762-Part 1 QD | Week3;n=1,2,1,3,4,6,16,6 | 149.14 Liters | Geometric Coefficient of Variation 26.9 |